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Abstract. Understanding the basic biology of human
ageing is a key milestone in attempting to ameliorate
the deleterious consequences of old age. This is an
urgent research prioritygiventheglobaldemographic
shift towards an ageing population. Although some
molecular pathways that have been proposed to
contribute to ageing have been discovered using
classical biochemistry and genetics, the complex,
polygenic and stochastic nature of ageing is such that
the process as awhole is not immediately amenable to
biochemical analysis. Thus, attempts have been made
to elucidate the causes of monogenic progeroid
disorders that recapitulate some, if not all, features
of normal ageing in the hope that this may contribute
to our understanding of normal human ageing. Two
canonical progeroid disorders are Werner s syndrome
and Hutchinson-Gilford progeroid syndrome (also
known as progeria). Because such disorders are
essentially phenocopies of ageing, rather than ageing
itself, advances made in understanding their patho-
genesis must always be contextualised within theories
proposed to help explain how the normal process
operates. One such possible ageing mechanism is
described by the cell senescence hypothesis of ageing.
Here, we discuss this hypothesis and demonstrate that
it provides a plausible explanation for many of the
ageing phenotypes seen in Werner s syndrome and
Hutchinson-Gilford progeriod syndrome. The recent
exciting advances made in potential therapies for
these two syndromes are also reviewed.
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Introduction: why study ageing?
Ageing presents a worldwide social and financial
challenge: by the year 2050, more than two billion
people will be over the age of 65 [1]. Long-term care
costs of the ageing population in the United Kingdom
alone are estimated at  £60 billion by 2030. Thus, the
effects of the ageing process are predicted to be the
major global health care challenge of this century [2].
In humans, ageing is associated with a subset of
diseases and crippling conditions including cardiovas-
culardisorders,diabetes,neoplasms,cataract,macular
degeneration, osteoporosis and auditory impairment
which result in frank ill health and low quality of later
life. However, ageing organisms are also frequently
subject to severe physiological frailty resulting in
tolerable performance under  normal  circumstances
but very poor survival chances if the organism is
placed under stress. This is most clearly seen in the * Corresponding author.
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Cellular and Molecular Life Sciencesimmune system where adequate protection against
infection is normally afforded by the ageing immune
system, but where disease susceptibility increases
markedly following physical or psychological traumas
thatdonotaffectimmunefunctionintheyoung[3–5].
Understanding the mechanisms of human ageing may
therefore give important insights into the pathogen-
esis of a range of age-related diseases and also has the
potential to allow intervention before overt degener-
ative pathology has developed.
Progress in understanding the basic biology of ageing
has been rapid over the last 10 years and has reached
the point where clinical interventions aimed at
ameliorating at least some aspects of the ageing
process can be envisaged. However, the complexity
of ageing requires an understanding of biological
processes at multiple levels, from molecules through
cells to tissues, organs and the organism, i.e. an
integrative biology. We contend that an integrative
approach is of particular value in the study of ageing
because its evolution contrasts sharply with that of
many biochemical pathways.
Approaches to studying ageing
Ageing is essentially an evolutionary side effect of
millions of years of selection for reproductive success.
Thus, the genetic basis of the process is potentially
extremelybroad and the  ageing  phenotype observed
asaresultofgeneactionmaybequitedistinctfromthe
primary role which the gene product plays in the life
history of the organism [6–10]. It has been estimated
that thousands of genes could play a role in determin-
ing lifespan in Homo sapiens [11]. However, much of
thescientificliteraturewithingerontologycanberead
as though single, simple mechanisms of ageing are
pitted against each other as alternative and mutually
exclusive explanatory theories for how ageing occurs.
Such single-mechanism views appear to us rather
naive. Similarly, because so many loci and pathways
are involved in the production of an essentially  soft 
phenotype (robust survival, as opposed to a  hard 
monogenic phenotype such as eye colour), the iden-
tification of candidate genes for successful ageing in
humans, although probably feasible, is unlikely to
occur either quickly or unambiguously.
Animal models of ageing have proven useful in
identifying individual genes or biochemical pathways
important in longevity, such as the IGF-1 axis in the
nematode Caenorhabditis elegans and fruit fly Dro-
sophila melanogaster [12, 13]. Whilst such systems are
clearly reflective of many aspects of ageing in higher
organisms[R.D.C.Saunders,I.Boubriak,D.J.Clancy,
L.S. Cox, unpublished data], they may have less
relevance to the senescence of mitotically active adult
cells in humans. Rodent models have therefore been
developed (discussed further below), but the direct
applicability of data from these systems again may be
ratherlimitedwithrespecttohumans.Manyspeciesof
rodentinvestmoreheavilyinreproductionandfarless
in maintenance of the soma than do humans, and as a
result susceptibility to oxidative stress and several
genome stability and DNA repair pathways differ
significantly between different rodent species and
between rodents and humans [14, 15]. Thus, these
models trade utility for direct physiological relevance
to the human situation.
Progeroid syndromes
Analternativeapproachtounderstandinghowhuman
ageing operates, which complements those briefly
outlined above, is the study of heritable genetic
diseases which mimic some, but not all, the features
ofnormalageing,inordertogaininsightsintohowthe
ageing process functions in normal individuals [11,
16–18].Originallyidentifiedbyanunbiasedappraisal
of the number of cardinal signs of normal human
ageing,whichappearasclinicalfeatureswithinagiven
genetic disease, these progeroid syndromes are
classed as either unimodal disorders (which show
only very limited aspects of human ageing such as
increased cancer incidence or rapid neurodegenera-
tion) or segmental disorders,which show a wide range
of ageing-specific phenotypes across multiple tissue
and organ systems.
The study of such progeroid syndromes has the
advantage that mutation of only a single gene is
usually causative in each case. This renders hypoth-
eses easier to frame and test and allows the power of
moderngeneticsandcellbiologytobebroughttobear
withpeculiarforce.Thedisadvantageofstudyingsuch
disorders is that they are essentially phenocopies of
normal ageing rather than the genuine article. We
focus upon the two canonical segmental progeroid
syndromes, Werner s syndrome (WS) and Hutchin-
son-Gilford progeroid syndrome (HGPS), because
these are the best understood with regard to their
pathology. That pathology is most consistent with the
cell senescence hypothesis of ageing which has been
proposed to account for many aspects of the ageing of
mitotic tissue in normal individuals. We outline this
hypothesis below, but wish to sound a note of caution
at the outset. The genes mutated in these disorders
participateinawidevarietyofpathwaysandprocesses
(which we have attempted to capture). However,
simple participation in a biological process does not
makeageneproductthecentralplayerinthatprocess,
and being the central player in a cellular process does
notmakethatcellularprocessthecardinalmechanism
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the whole organism. The relationship between geno-
type and phenotype in WS in particular illustrates this
degree of systemic complexity rather well.
The cell senescence hypothesis of ageing
The cell senescence hypothesis of ageing proposes
that the progressive accumulation of senescent cells
contributes to, but does not exclusively cause, the
ageing of the tissue in which they reside. Senescence
(sometimescalledreplicativesenescenceforclarity)is
a permanent block to division in cells from the mitotic
tissue compartments of metazoans [19]. This block
can be established in a wide variety of ways which
result in a viable but permanently non-dividing cell.
Senescent cells display many biochemical features
that are distinct from their proliferating counterparts
as a result of widespread changes in the transciptome
[20, 21]. Overall, the differences between senescent
cells and their growing counterparts are as large as
those observed during cell differentiation [22].
Although failure to divide in response to a mitotic
stimulus is the hallmark of senescent cells, not every
non-dividing cell is senescent. Senescence is distinct
from quiescence (transient growth arrest), and in
systemswhereitispossibletoexperimentallyseparate
the two, senescence is distinct from terminal differ-
entiation [23, 24].
Senescencehasthepotentialtocontributetoageingin
at least two distinct ways: (i) through simple loss of
proliferative capacity; (ii) through alterations in the
tissue microenvironment as a result of the accumu-
lation of cells with an altered phenotype. Three types
ofobjectionhavebeenmadetotheideathatsenescent
cells play a role in the ageing process. These can be
simply summarised as:
(i) Senescencedoesnotexistinvivo.Itsimplyresults
from tissue culture conditions so deficient that the
mechanismsby whichgrowth arrest occurs invitro are
unlikely ever to occur in the normal animal.
(ii) Senescence does occur in vivo but so few cells
ever become senescent that any effects they might
have are so small that they can be discounted.
(iii) Senescent cells do occur in vivo at appreciable
frequencies. However, the phenotypic differences
between them and their growth-competent counter-
parts are trivial. Essentially, they are present but they
do no harm.
The first of these objections focuses on how senescent
cells occur, the second on the frequency with which
they occur and the third on whether senescent cells
canexertadeleteriouseffect.Sufficientdatahavenow
been accumulated to counteract these objections.
These data are derived from the culture dynamics of
normal cells grown in vitro, the detection of senescent
cells in vivo and the behaviour of such cells both ex
vivo and in vivo. It should be noted that none of these
linesofevidencerequiresthatcellsbecomessenescent
byaparticularpathway,merelythattheyhaveentered
the senescent state. Some of these findings are
touchedonbelowbut space precludes afulltreatment
of the subject.
Perhaps the best evidence against the idea of sen-
escence as a tissue culture artefact is the body of data
which demonstrates that primary cell populations are
mixtures of clones with very variable intrinsic growth
potentials which co-exist in the same medium. The
thrustoftheseexperimentsisexemplifiedinaseriesof
studiesinwhichthetwodaughtercellsresultingfroma
single mitotic event were separated immediately
following cytokinesis and their replicative capacity
determined. Such daughter cells differ by up to 2
8 in
their proliferative capability [25]. Such large differ-
encesinproliferationbetweenidenticaldaughtercells
are difficult to reconcile with issues of establishment
of cell culture or simply  poor tissue culture . This
divisional behaviour also leads to the appearance of
senescent cells with very limited capacity for cell
division,consistentwiththeirappearanceoverthelife
course ofahuman [26–28].However,thisisnotproof
that such cells exist in tissue.
Fortunately, several studies using different method-
ologies designed to detect senescent cells in vivo have
now directly demonstrated their appearance and
accumulation with age in a variety of human, primate
and rodent tissues [29–31]. The most recent of these
[32, 33] has shown that at least 15% of all dermal cells
in very old baboons can be classed as senescent (by
immunocytochemical detection of makers of the
senescent state). Whilst there will always be argu-
ments about the number of cells required to exert an
effect, it is not unreasonable to conclude that changes
on this scale could produce degenerative effects if
senescent cells are capable of exerting them. Indeed,
senescent cells have been shown to adopt a secretory
phenotype that adversely impacts on their local
environment [34].
Direct measurement of senescent cells in vivo is
always superior to attempts to infer their presence
throughthegrowthanalysisofbiopsies.Howeversuch
studies occasionally appear in the literature and thus
need to be considered. The classic studies in this area
reported an inverse correlation between donor age
and the number of population doublings achieved in
vitro when cells from donors of undefined health
status were used [35], or a sharp decline in prolifer-
ative capacity of cells from subjects who were either
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proliferative capacity in healthy controls [36].
Similar studies have been conducted more recently
using fibroblast cultures derived from the Baltimore
LongitudinalSurveyonageingandtheLeiden85-Plus
study [37, 38]. These demonstrate no statistically
significant decline in the replicative potential of
fibroblasts derived from healthy donors (the Leiden
study also failed to show a proliferation reduction in a
small number of donors with diabetes).
At first sight, these observations seem difficult to
reconcile with the idea that there is a relationship
between cell senescence and ageing, and it is a great
pity that no large-scale studies have yet been per-
formed which combine detection of senescent cells in
vivo with the growth capacity of the same biopsy
material in vitro. It is of course possible to invoke
immediate technical difficulties (e.g. a selection
process that occurs during establishment of cultures
from biopsies, or limited powers of the study) as an
explanation for the failure to observe a reduction in
growth capacity in old material. However the failure
to observe differences in proliferative capacity could,
in fact, be quite consistent with the cell senescence
hypothesis. An explicit prediction of the theory is that
senescentcellsarecausalagentsofageinganddisease.
It would be close to direct disproof of the theory if the
mitotic tissues of the elderly were full of senescent
cells but showed no diminution in physiological
function. This has never been shown to occur and
could only arise if senescent cells were incapable of
exerting degenerative effects.
Perhaps the best evidence that senescent cells can
reallyexertsignificant ageing effectsisprovidedbya
study in which human dermal populations aged in
vitrowereincorporatedintoreconstitutedhumanskin
equivalents. Dermal fragility and subepidermal blis-
tering increased in this system with increasing num-
bers of senescent cells [39]. A still more striking
demonstration that senescent cells can produce life-
threatening pathology was provided by experimental
induction of senescence in living rat carotid arteries.
This produced severe vascular inflammation and
changes consistent with the development of atheroma
[40]. This study should be regarded as a landmark in
the relationship between cell senescence and organ-
ismal ageing.
Molecular mechanisms of cellular senescence
Replicative senescence exists as a mechanism for
tumour suppression [41–43], balancing the require-
ment for cells to proliferate and the inherent risk of
neoplastictransformationwiththelossofproliferative
capacity which leads to tissue dysfunction. As a result
of its importance in carcinogenesis, there is a large
literature on the mechanisms by which cells enter a
senescent state. A comprehensive treatment of this is
beyond the scope of our review, so only a brief and
broad overview of the area is given below.
The role of senescence in tumour suppression is
probably best illustrated by the observation that both
rodentandhumancells(ofseveraldifferenttypes)will
enter a state of senescence in the presence of high-
grade stimulation of the proto-oncogenic ras pathway
(typicallyachievedbyectopicexpressionofoncogenic
K-ras V12) [44]. Acute exposure to ceramide [45] or
DNA-damaging agents can also trigger this reactive
style of senescence which probably contributes to the
presence of at least some senescent cells in vivo.
Cells will also enter senescence via a series of intrinsic
constitutivepathwaysthatdonotrequirethepresence
of exogenous agents. Many normal human cell types
enter  telomere-dependent senescence  as a result of
the loss of chromosomal ends (telomeres) at each
roundofDNAreplication.Eventuallythisprogressive
telomere attrition triggers a p53-dependent cell cycle
arrest leading to senescence. p53 is a driver of
senescence as determined from the premature ageing
phenotypes observed in mice expressing  hyper-ac-
tive  p53 [46], although p53-independent telomere-
dependent senescence has been reported in cells with
experimentally induced telomere instability [47]. p53
isalsoasignificantfactorinmaintainingthesenescent
state:p53ablationbyubiquitin-mediateddegradation
(through ectopic HPV E6 expression) or neutralisa-
tion by antibody microinjection releases cells from
senescence [48]. However, not all human cell types
use this pathway as an initial proliferative lifespan
barrier. Some, notably keratinocytes and pancreatic b
cells, primarily enter senescence through the p16-pRb
pathway [49] (so-called  telomere-independent sen-
escence ).Humanglialcellsenterasenescentstatevia
the activation of p19
ARF , leading to downstream
induction of both p53 and its transcriptional target
p21
CDKN1 [50–52]. This state has been termed  p53-
dependent telomere-independent senescence  [53].
Significantly, p19
ARF seems to provide a response to
oncogenic stress through the p53 pathway [reviewed
inref.54].Thusp53anditsactivatorsandeffectorsare
intimately linked to the onset and establishment of
senescence, which may account, at least in part, for its
potent activity as a tumour suppressor.
Cross-species studies also complicate the mechanistic
picture. Rodents in particular do not show telomere-
dependent senescence, and fibroblasts from these
animals normally enter senescence despite long
telomeres and the presence of high levels of the
telomere maintenance enzyme, telomerase. Normal
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to that induced by the p19
ARF pathway than the
classical telomere-p53 axis seen in human fibroblasts.
Mice lacking the catalytic component of telomerase
(terc–/–) show premature ageing after five to six
generations[55].Theprimaryphenotypesobservedin
this system seem to be driven by apoptosis as result of
chromosomal uncapping rather than senescence
(though apoptosis-driven proliferation to repopulate
depleted tissues may in itself accelerate the onset of
senescence,particularlyintheabsenceoftelomerase).
Rescue of fertility and germ cell viability in terc–/–
mice with short telomeres by additional loss of p53
serves to highlight the importance of p53 in triggering
theresponsetotelomerelossinsuchtransgenicrodent
systems [56]. Very recently, p21
CDKN1 deficiency has
been shown to increase lifespan and rescue prolifer-
ative defects of both haemopoietic stem cells and gut
epithelium in mice with pathologically short telo-
meres [57], without increasing cancer susceptibility.
These results strongly suggest that p21 is involved in
the response of rodent cells to aphysiologically short
telomeres. These observations underscore the close
relationship between the senescent state and apopto-
sis, suggesting that whether a given cell will die or
senesce in response to pathological stimuli is highly
cell type and context dependent.
Werner s syndrome
WS, first described by Otto Werner in 1904 [58],
provides perhaps the best current model of normal
human ageing. Cardinal features include bilateral
cataracts, grey hair, skin abnormalities, short stature
and hyaluronic acid excretion. In addition to the
cardinal signs, a range of clinical problems are widely
penetrant, from hoarse voice, alopecia, diabetes, soft-
tissue calcification with ulceration, atherosclerosis,
arteriosclerosis, osteoporosis, T cell atrophy (leading
to immunodeficiency) and a greatly elevated risk of
developing a subset of cancers, predominantly sarco-
mas. Patients are generally of small stature and very
low body weight with little subcutaneous fat, but have
an unusual redistribution of fatty deposits around the
abdominal region reminiscent of morbid obesity and
correlating with greatly increased risk of myocardial
infarction [59] (see also International Registry Of
Werner Syndrome: http://www.pathology.washingto-
n.edu/research/werner/registry/registry.html). Their
increasedatherosclerosis and hyperlipidaemiapredis-
poses to transient ischaemic attacks with possible
neurological consequences [60]. Schizophrenia and
senile dementia are also elevated in Werner s patients
[61, 62], but there is no association of WRN protein
variants with Alzheimer s disease [63]. With greater
clinical recognition of the syndrome, together with
improvements in cancer detection and treatment, and
health screening programmes, the median age of
death ofWerner s patients hasincreasedfrom47 to57
years [64, 65]. Remarkably, this wide range of clinical
phenotypes that provide a fairly comprehensive
phenocopy of normal ageing results from mutation
of the single WRN gene. How can this be accounted
for?
The WRN gene
The human gene responsible for WS is located on
chromosome8p12-p11.2[66–68].Itencodesaprotein
of 1432 amino acids with homology to the RecQ
family of helicases [reviewed in ref. 69), and the
DEAHboxfamilyofRNAhelicases[70],anditshows
3’–5’ helicase activity in vitro [71]. WRN shares
ATPase and single-strand (ss) DNA strand annealing
activities with other members of the RecQ family.
Conserved HRDC and RQC domains are located C
terminal to the helicase region. Enzymatically, WRN
is unique amongst the RecQ family in that it also
possesses an amino-terminal 3’–5’ exonuclease do-
main [72]. At the C terminus is a nuclear localisation
sequence (aa 1358–1432) and a nucleolar localisation
sequence ([73]; either at amino acids 949–1092 [74],
or R1403 and K1404 [75]). Consistent with this, WRN
is generally sequestered in the nucleolus [76], co-
localising with nucleolin (inhibition of its helicase
activity by nucleolin has been suggested [77]).
The vast majority of patient-derived WRN mutations
encode a truncated protein lacking the C-terminal
nuclear localisation sequence, and hence are not
targetedtothenucleus[78].Additionally,thestability
ofWRNmRNAsbearingsuchmutationsislowerthan
thatofintactWRNmessage[79],suggestingthatRNA
surveillance and nonsense-mediated decay are re-
sponsible for maintaining the very low levels of WRN
mRNA in patient cells [80]. By contrast, two missense
mutations have recently been described where the
mRNA is stable but the WRN protein product is
unstable [65]. These mutations lie beyond the exonu-
clease active site and are likely to impact on folding in
this domain rather than enzymatic activity per se [81].
A further polymorphism/mutation has been reported
that abolishes helicase and helicase-associated nucle-
ase activity (polymorphism R834C [82]). Various
other polymorphisms have been described [83–85].
Of these, there is some controversy over R1367C,
which shows no association with longevity in Finnish
centenarianstudies[86],althoughithasbeenreported
to be protective against myocardial infarction in
Japanese populations [87]. However, this finding was
notsupportedbydatafromtheBaltimorelongitudinal
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WRN enzyme activity was detected [88]. Whilst it is
notatfirstsightsurprisingthatanenzymaticallyintact
WRN variant has no detectable effect on human
disease incidence, WRN may also function by recruit-
ing proteins via its non-enzymatic RQC or HRDC
domains. We cannot at this stage rule out the
possibility that genetic background contributes to
the impact of particular WRN polymorphisms. In-
deed, significant differences between WRN polymor-
phismsindifferentracialgroupsarehighlightedbythe
HapMap project (http://egp.gs.washington.edu/gty_-
data/wrn/, also www.hapmap.org), though it is too
early to determine which, if any, differences might
impact on human lifespan.
WRN in DNA metabolism
The domain structure and nuclear/nucleolar local-
isation of the WRN protein suggest a role in DNA
metabolism (replication, repair, recombination or
transcription; see Fig. 1), and at least in vitro, WRN
helicase and exonuclease activities are directed to-
wards DNA structures mimicking those found in
DNA replication (forks), DNA recombination (four-
way junctions), transcription (loops) and telomere
maintenance (G4 tetraplexes) [89; reviewed in ref.
77].AhallmarkphenotypeofWScellsishighlevelsof
genome instability [90–92], and it is significant that
epigenetic inactivation of human WRN can lead to
genomic instability and human cancer [93]. However,
the complex phenotype of cells from WS patients (see
below) does not reveal directly the mode of action of
WRN.Itispossiblethatthiscomplexityistheresultof
enormous pleiotropy of WRN action in many or all
aspects of DNA metabolism. Since it is not yet clear
which of these processes may be the primary driver of
premature senescence in WS, we review below all
aspects in which WRN has been implicated exper-
imentally.
DNA replication
WRN is important in, though not essential for, DNA
replication, as shown by a wide range of studies, from
in vitro biochemistry to whole-cell analysis. First,
purified recombinant WRN protein assayed in vitro
for helicase activity shows a marked preference for
replication fork-like oligonucleotide templates [re-
viewed in ref. 77]. Moreover, WRN protein extracted
from cultured cells co-purifies with a very large
replication complex containing the essential DNA
polymerase processivity factor, PCNA [94]. Interac-
tion with PCNA occurs through a classical PCNA-
binding motif [95, 96] within the exonuclease domain
of WRN [97]. Additionally, the C-terminal domain of
WRNbindstoanessentialreplicationnuclease,FEN1
[98, 99] required for processing Okazaki fragments on
the lagging strand of the replication fork [100],
stimulating Fen endonuclease cleavage of 5’-flap or
Figure 1. Pleiotropy of WRN action in DNA metabolism. WRN affects all key aspects of DNA metabolism (boxed), either directly
through its helicase and exonuclease activities, or mediated through multiple protein-protein interactions (grey ovals – for clarity only a
subsetofknowninteractingproteinsareshown)Inappropriate executionoftheseprocessesintheabsenceofWRNleadstothemolecular
outcomes shown below the arrows.
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implicated in processing stalled replication forks
[102], an activity also suggested for WRN [103–
105]. As the WRN-binding site on Fen1 is adjacent to
but does not overlap that of PCNA, it is possible that
all three proteins can act co-ordinately [106].
Consistentwithitsinteractionwithreplicationfactors,
WRN moves to replication foci in S phase and co-
localises with replication factors such as PCNA [97]
and RPA [107]. Although WRN is present at a large
subset of replication foci (60% in normal primary
human fibroblasts [104]), it is not needed to establish
such sites, as formation and progressive morpholog-
ical changes in S phase foci are indistinguishable
between WS and normal fibroblasts [104]. Phenotypi-
cally, cells have an apparent problem with DNA
replication: cultured WS lymphoblastoid cells and
fibroblasts have an extended cell cycle with a delayed
Sphase[104,108,109]whichisnotafeatureofnormal
senescent cells [110].
DNA fibre autoradiography studies of whole-cell
populations suggest that replication origins are more
widely dispersed in WS fibroblasts than in normal
controls[111,112],consistentwithadefectatthelevel
oforiginfiring.ConfocalmicroscopyofcombedDNA
from synchronised WS fibroblasts demonstrated that
replication fork progression is aberrant, with the
majority of bidirectional origins showing significant
fork asymmetry [104], suggesting an accumulation of
stalled replication forks in WS fibroblasts. This
hypothesis has very recently been tested by resolving
the four-way DNA junctions predicted to form at
stalled forks, which rescues the characteristic WS
phenotypes of poor proliferation, low S phase pop-
ulations and hypersensitivity to camptothecin [105].
Moreover, in vitro studies have shown that WRN can
regress replication fork-like structures [113].
Further support for a role of WRN at the replication
fork comes from the finding that WS fibroblasts and
lymphoblastoid cells are hypersensitive to the top-
oisomerase I poison camptothecin [114–116]; at-
tempts to replicate over camptothecin-induced sin-
gle-strand breaks is thought to lead to replication fork
collapse [117]. Moreover, a functional association of
WRN with TopoI has been demonstrated [118].
Taken together, these results suggest that WRN may
play a role in restarting stalled replication forks or in
preventing the accumulation of recombination inter-
mediates such as Holiday junctions at collapsed forks
[105].Thismaybeofparticularsignificanceduringthe
replication of repetitive DNA or genomic regions
containing replication fork barriers such as the rDNA
[119, 120]. It is noteworthy that yeast cells mutant for
the WRN homologue Sgs1 show excessive recombi-
nation of rDNA, resulting in extrusion of rDNA
circles [121]. Accumulation of such extrachromoso-
mal rDNA circles strongly correlates with senescence
[122].
Telomere maintenance
WRN may be involved in telomere maintenance as
well as during global DNA replication. Purified
recombinant WRN protein can act on G4 tetraplex
and D-loop structures analogous to telomeric DNA
[123, 124]. Not only does WRN bind to the telomere-
capping protein TRF2, but this interaction also
regulates the exonuclease and helicase activities of
WRN on telomere-like DNA [125–127]. WRN co-
localises with telomeres in ALT cells [127], telomere
replication appears aberrant in cells expressing a
dominantnegativeWRNhelicase[128],andtelomere
abnormalities have been described in WS cells [129,
130], though single telomere length measurements on
the X chromosome have shown roughly normal rates
of telomeric attrition in WS [131]. Additionally, the
very low proliferative capacity of WS fibroblasts can
beovercomebyectopicexpressionofhuman telomer-
ase [132]. These findings are suggestive that telomere
defects may be causal in WS senescence [133, 134],
supported by very recent data indicating that altered
telomere dynamics can lead to genomic instability in
WS [135, 136].
DNA recombination
There are many lines of evidence suggesting that
WRN is important in homologous recombination
(HR),notleastitsfunctionalordirectassociationwith
recombination proteins such as Rad51 [137] and
Rad52 [138]. Recombination is aberrant in cells
lacking functional WRN [139], WRN can suppress
illegitimate recombination in yeast cells defective for
the homologue Sgs1 [140], and the Schistosaccharo-
myces pombe homologue Rqh1 is required for sup-
pression of homologous recombination, permitting
transient S phase arrest on damage [141]. All these
lines of data further support a role for WRN in
restraining recombination. Moreover, a hypomorphic
mutation of the Drosophila WRN exonuclease results
in extremely high levels of somatic recombination
[Saunders et al., unpublished data]. The prokaryotic
Holliday junction resolvase, RusA, can complement
WS cellsto permitrecombination and survival follow-
ing cis-platin damage to DNA, apparently acting
downstreamfromRad51[137].Insupportofthisidea,
WRNinteractswiththeDSBresponsecomplexMRN,
probably via Nbs1 which acts either upstream or
downstream of Rad51 [142–144]. Moreover, RusA
expression restores S phase progression and prolifer-
ative capacity to WS fibroblasts [105], phenotypes
that are presumed to result from excessive accumu-
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replication forks. This strongly suggests either that
WRN acts directly in HR, or that it prevents the
accumulationofsubstratesthatareotherwiseresolved
via recombinational mechanisms. The hyper-recom-
bination seen in WS patient cells [92] is more
supportive of the latter hypothesis. Interestingly,
dissolution of double Holliday junctions by BLM, in
combination with BLAP and TopoIIIa [145, 146],
requires the HRDC domain [147]; domain swap
experiments with WRN HRDC should prove inter-
esting.
In addition to accurate HR, WRN is implicated in the
error-prone recombinational pathway of non-homol-
ogous end joining (NHEJ) [148]. In a plasmid-based
assay for NHEJ in transfected WS cells, large deletion
products were formed [149], with products differing
according to whether DNA had 5’ overhang, 3’
overhang or blunt ends, and a  balance  between
exonuclease and helicase activities was postulated to
be important in mediating correct processing without
excessive deletion [150]. Interestingly, the Ku hetero-
dimer, an essential factor for NHEJ, is a known
protein partner of WRN, stimulating its exonuclease
activity [151,152], while double deletion of WRN and
Ku leads to lower sensitivity to camptothecin [153]. It
is possible that WRN may act exonucleolytically in
NHEJ when its helicase activity is repressed. Surpris-
ingly, NHEJ in WS cells can be complemented by a
mutant variant of WRN that lacks both helicase and
exonuclease function (complementation by each sin-
gle-pointmutantformwaspartial)[150].Thissuggests
that WRN may recruit factors necessary for NHEJ
rather than, or in addition to, acting enzymatically.
DNA repair
WS cells are hypersensitive to a specific subset of
DNA-damaging agents including 4NQO [105, 154]
andaccumulatealargenumberofoxidativelesionson
exposure to H2O2 [155] or under normal culture
conditions [156]. These findings are suggestive of
problems in dealing with oxidative damage through
the base excision repair (BER) pathway. Recently, it
has been demonstrated that both patient-derived WS
and RNAi-WRN-knockdown cells are also hyper-
sensitive to methylating agents [157, 158]. Alkyl and
oxidative lesions in DNA are normally processed
through the BER pathway, of which there are two
distinct biochemical routes. The first allows simple
removal of the damaged base by a glycosylase, with
cleavage of the phosphodiester backbone by an AP
endonucleaseattheresultingapurinic/apyrimidicsite.
Replacement synthesis by DNA pol b then ligation by
DNA ligase 1 repairs the lesion quickly and precisely.
WRN physically interacts with and stimulates DNA
polymerase b, in vitro [159, 160], and WRN helicase
activity is inhibited by AP1 endonuclease, with
inhibition relieved by DNA pol b [159, 161].
An alternative  long patch  BER pathway also exists
[162], requiring the action of the same enzymes
employed in Okazaki fragment processing: interest-
ingly, WRN interacts with many of these components,
including PCNA [94, 97], RPA [163] and Fen1 [98].
Furthermore, WRN interacts with the poly(ADP-
ribosyl) polymerase (PARP1) [164, 165], important in
damage signalling. Such binding is thought to modu-
late the helicase and exonuclease activities of WRN
andoccursshortlyafteroxidativeandalkylatingDNA
damage and prior to caspase cleavage of PARP [Cox,
unpublished data]. Taken together, it is highly likely
that WRN is involved both in single-nucleotide
( short-patch ) and long-patch BER.
Transcriptional regulation
Global transcription, as assayed by
3H-uridine incor-
poration, is decreased in WS compared with normal
controls, and this is seen especially in the nucleolus
[166], suggesting an impact of WRN on RNA
polymerase I transcription that may be direct or
through provision of an accessible template. rRNA
transcription is enhanced by WRN interaction with
RNA polymerase I [167]. Additionally, a role for
WRN in RNA polymerase II-mediated transcription
has been shown in permeabilised cells and in vitro
studies [168]; furthermore, loss of WRN may result in
lower basal levels of transcription through inability to
resolve unusual DNA or chromatin structures. It is
interesting that WRN is required to prevent the
accumulation of overt DNA double-strand breaks
upon treatment with the chromatin-modifying drugs
chloroquine and trichostatin [169], supporting a role
for WRN in maintaining a template competent for
both transcription and replication.
It is possible that WRN may play further regulatory
functions in controlling gene expression, given the
action of WRN homologues in evolutionarily distant
species. For example, a RecQ in Neurospora crassa
and Mut-7 in C. elegans are both involved in RISC-
dependent RNA silencing [170, 171], and the WRN
exonuclease homologue in Arabidposis thaliana,
WEX, mediates post-transcriptional gene silencing
[172]. Human WRN has not at present been shown to
possess similar activities, though experimental diffi-
culties in obtaining stable RNAi knockdown of WRN
[L. S. Cox, R. G. A. Faragher unpublished data] are
provocative.
Chromosome segregation and stability
Correct segregation of mitotic chromosomes is essen-
tial to maintain gene and chromosome copy number
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strate that chromosome segregation is aberrant when
Sgs1 or Rqh1 are mutated [173, 174]; this may reflect
an indirect (via checkpoint activation) or a direct
action of these homologues on chromosome segrega-
tion mechanisms. It is therefore possible that WRN
mayplayaroleinsisterchromatidcohesionorrelease
of cohesion at mitosis. Interestingly, cohesion is
established in S phase [175], a time when WRN
migrates to the nucleoplasm and sites of DNA syn-
thesis [97, 104, 107]. It will be interesting to explore
more rigorously a possible role of WRN in chromatid
segregation.
It is equally possible that WRN (or its yeast homo-
logues) is important in chromosome segregation
through the spindle checkpoint. By comparison,
another human RecQ protein, BLM, is phosphory-
lated during mitosis by the MPS-1 kinase, and
phosphorylated BLM then interacts with polo-like
kinase 1. A BLM point mutation (S144A) that cannot
be phosphorylated by MPS1 supports normal rates of
sister chromatid exchange (SCE) (Bloom s syndrome
(BS) is characterised by excessive SCEs) but cannot
maintain mitotic arrest on MPS1 activation through
the spindle checkpoint [176].
Impact of WRN loss on cells and tissues
Probably the most interesting question which can be
asked when considering WS is how loss-of-function
mutations in WRN produce the pleiotropic  ageing 
phenotype seen in the patient. This requires the
application of integrative biology, moving beyond the
gene to the cell and the tissue.
Atthecellularlevel,WSfibroblastsshowprobablythe
most limited divisional capacity of any human cells.
Ninety percent of all WS fibroblast cultures enter
senescence after proliferating for fewer than 20
population doublings [177]. This premature senes-
cenceresultsfromveryrapidratesofexitfromthecell
cyclecomparedtonormalcontrols[178].Themultiple
roles of WRN in DNA metabolism and the known
hypersensitivity of WRN null cells to agents such as
camptothecin immediately suggest that elevated
DNA damage (essentially occurring at random across
the genome) may cause the poor ability to grow. The
alternative to arrest due to this sort of dispersed
damagewouldbethatWSfibroblastsshowpremature
senescence as a result of an acceleration of telomere-
driven senescence. Elevated telomeric deletion from
single sister chromatids and telomeric dysfunction
have been reported recently and several groups have
shown that Werner s syndrome fibroblasts can be
immortalised by ectopic expression of telomerase
[132, 179, 180]. This suggests a primary role for
telomereshorteningasthedriveroftheshortlifespan;
however attempts to demonstrate a consistently
increasedrateoftelomerelosshavebeenunsuccessful
[131],suggestingthatitisnotgoingon!Howarethese
data to be interpreted?
A helpful observation is that not all types of WS cells
senesceprematurely,thoughallofthemshowfeatures
consistent with aberrant DNA metabolism (see
above). The best characterised example of this is
foundinTcellsderivedfromWSpatients.Theseshow
no reduction in growth capacity compared to normal
controls [181] but are hypersensitive to DNA-damag-
ing agents with aberrations consistent with being null
for WRN [177, 182]. Fibroblasts and T cells differ in
their expression levels of telomerase (it is essentially
absent in fibroblasts but is induced upon activation in
T cells). These differences have been generalised into
models which suggest that the effects of WRN loss on
the ability to grow will depend on the controls on
replicative lifespan of the cell type in question [133,
134, 183]. The best working model for how WS cells
become senescent is therefore a mixture of irrever-
sible cell cycle exit and accelerated telomere-driven
senescence. These molecular insights provide impor-
tant clues to potential therapeutic routes (see below).
The observation that premature replicative senes-
cence is not a universal response to a lack of WRN
provides a satisfying explanation for the most obvious
clinical difference between WS patients and normal
ageing humans. WS patients show multiple but tissue-
specific decline in functional capacity. Some tissues
(such as the dermal layer of the skin or the bones) are
very severely affected by the disease whilst some
others, notably the immune system, are essentially
normal. In contrast, normal older people show a
pattern of consistent decline across multiple organ
systems. We do not see geriatric humans with the
bones of a centenarian and the T cells of a teenager.
Something close to this is observed in WS.
Perhaps the best evidence that replicative senescence
plays a major role in the clinical presentation of the
syndrome comes from Wrn knockout mice. Animals
lacking WRN alone show few premature ageing
phenotypes despite the fact that their cells show a
mutator phenotype characteristic of the disease and
increased sensitivity to the effects of several DNA-
damaging agents [184, 185]. Most notably, the pre-
mature replicative senescence seen in human WS
fibroblasts was not recapitulated in this model. Thus
simple genomic instability is not in itself sufficient to
replicate the WS phenotype in rodents. In contrast
Wrn/Terc double mutants develop age-dependent
pathologies very similar to those seen in WS humans
(including grey hair, osteoporosis, type II diabetes,
cataracts, an elevated frequency of non-epithelial
malignancies and premature death). Fibroblasts
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damaging agents and accelerated replicative senes-
cenceinvitro[186].Thus,lossofWRNappearsonlyto
give a profound phenotype if senescent cells are
generated at accelerated rates.
The accumulation of senescent cells with their proin-
flammatory phenotype provides a good potential
explanation for the development of many of the
pathologies seen in the disease, but is this mechanism
the whole story? At least one clinical feature of the
disease seems unlikely to be caused simply by
senescent cells. This is the observation that WS
patients have elevated cancer frequencies for a
selected subset of mesenchymal neoplasms [187].
The increased frequency of these unusual tumours is
moreconsistentwiththegenomicinstabilitycausedby
loss of WRN than with an excessive generation of
senescent cells. Provocatively, this is also one of the
aspects of the disease which is most at variance with
the clinical presentation of normal elderly people.
In whole organisms, different tissue systems interact
to maintain physiological homeostasis. Thus a serious
perturbation in one tissue may have equally serious
effects on another even though the primary cause of
that perturbation is absent. Based on what we know
about cell division counting mechanisms, the cells of
the cardiovascular system (endothelium and vascular
smooth muscle) are not especially strong candidates
for a severe lifespan deficit in the absence of WRN.
However, cardiovascular disease is a striking feature
of WS, suggesting either that these cells will senes-
cenceprematurelyor thatsomeother mechanismisat
work. Although the replicative lifespans of vascular
cells from WS patients have yet to be formally
measured, there are at least some data to suggest
thatsystemicperturbations areplayingamajor rolein
this aspect of the phenotype.
WS patients accumulate visceral fat by an unknown
mechanism (probably due to altered cell turnover in
the pre-adipocyte compartment) and show a robust
phenotype of insulin resistance which is mediated by
high circulating levels of plasma tumour necrosis
factor (TNF)-a and low levels of adiponectin [188,
189]. Thus, although not morbidly obese, WS pa-
tients have cytokine profiles akin to those seen in
metabolic syndrome. Since severe cardiovascular
disorders (including atherosclerosis) are common in
metabolic syndrome, it is at least plausible that these
systemic factors are driving the disease in WS
patients. This pattern of pathology would be difficult
to explain simply in terms of a RecQ helicase
mutation, but an integrative approach allows the
ramifications of such a mutation to be conceptual-
ised.Thisalsogivesinsightsintopotentialtreatments
[see ref. 190 and below].
From genotype and phenotype to therapy in WS
The most important factors in increasing life expect-
ancy and quality of life for WS patients are early
diagnosis,regular monitoring and effective treatment,
particularly of neoplasia. The efficacy of such an
approach can be seen in the Japanese population,
where life expectancy of WS patients has increased
markedly over the past decade [64]. In addition to
these, an understanding of the key roles of WRN in
DNA metabolism (Fig. 1) may be central to providing
an effective therapy for those with the disease (see
also Fig. 3). In particular, the idea that the S phase
deficitresultsfromaccumulationofstalledreplication
forks, with concomitant accumulation of unusual
DNA structures such as Holliday junctions, has led
to the development of an experimental reversal of the
WS phenotypes of poor cell cycle progression and
drug sensitivity, by supplying an ectopic Holliday
junction-cleaving enzyme [105, 137]. Whilst not a
treatment option per se, these findings have high-
lighted the HR pathway components as potential
targets for intervention in WS.
Knowledge of the protein interactions of WRN and
importantly the signal transduction pathways that
transmit the signal from stalled replication forks or
broken DNA has led to an alternative strategy for WS
therapy. Inhibition of the p38 stress kinase, which is
involved in signal transduction from DNA damage to
cell cycle arrest, using the small-molecule compound
SB203580, appears to reverse not only the prolifer-
ative deficits of cultured WS fibroblasts but also their
gross morphological abnormalities, including a re-
structuring of the actin cytoskeleton [191]. WS
fibroblasts grow well in the presence of the drug and
although there are legitimate concerns that continued
proliferation may pose an increased cancer risk in WS
patients, correcting the proliferative defect may bring
real clinical benefit.
Lastly,thesystemiceffectsofWRNmutationsarealso
amenable to treatment. Fat distribution, serum adi-
ponectin levels and insulin resistance can all be
improved in WS patients by pioglitazone treatment
[188–190, 192], suggesting that this drug may be one
effectiveroutetoimprovingpatientlifeexpectancyby
decreasing risk of cardiovascular accidents. It is likely
that a combination of therapies targeting various
pathologies will be most effective in terms of clinical
outcome.
Hutchinson-Gilford progeroid syndrome
This is a very rare, severe infant-onset progeria in
whichchildrenmanifestmarkedsignsofageingwithin
their first year, with significant growth retardation
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patients, they suffer from alopecia, lipodystrophy,
osteoporosis, arteriosclerosis and atherosclerosis. The
major cause of death is myocardial infarction at
median age 11,due to coronary artery atherosclerosis.
Unlike WS, HGPS patients do not suffer from
cataracts or show neurological problems.
Identification of the HGPS gene
In 2003, the gene on human chromosome 1q21
responsible for HGPS was identified as LMNA [194,
195].Itislargegene(24kb)with12exonsandencodes
at least four distinct splice variant products [196, 197].
Of these, lamin A (75 kDa) and lamin C (64 kDa),
together with lamin B, which is encoded on a separate
locus, make up the 20- to 50-nm-thick intermediate
filament network of the nuclear lamina that underlies
and supports the nuclear envelope [reviewed in refs.
198, 199]. Unlike the cytoplasmic and extracellular
intermediate filaments, the lamins undergo rapid and
reversible depolymerisation at every cell division,
mediated through phosphorylation by the G2/M
phase cyclin-dependent kinases [200, 201]; lamin
repolymerisation promotes nuclear envelope reas-
sembly after mitosis [reviewed in refs 198, 202, 203].
Lamin A is initially synthesized as a precursor pre-
lamin A that undergoes farnesylation on a conserved
CAAX motif (cysteine-aliphatic-aliphatic-variable),
with subsequent cleavage in two stages to form a
maturelaminA(seeFig. 2)[reviewedinref.204].The
most common mutation in HGPS occurs in exon 11
leading to activation of an otherwise cryptic splice
donor site. Incorrect splicing then results in formation
of an aberrant mRNA lacking the last 150 nucleotides
of exon 11 [194, 195, 205, 206]. The encoded protein is
50 amino acids shorter than wild-type lamin A, and
lacks the cleavage sites usually recognised by the
NER-associated Zmpste24 metalloprotease, resulting
in accumulation of incorrectly processed pre-laminA,
also known as  progerin  or D50 lamin A. There are at
least two possible steps inthe processing pathway that
involve proteolysis; disruption of either would lead to
accumulationofpre-laminA(Fig. 2[seealsoref.204].
FromthisitcanbeseenthattheclassicLMNAG608G
mutation in HGPS results in formation of a truncated
pre-lamin A, whilst Zmpste24 mutation leads to
accumulation of wild-type pre-lamin A (the usual
lamin A precursor). Interestingly, other mutations in
lamin A cause human disease but with a different
phenotypic spectrum from HGPS [reviewed in refs
197, 207, 208; see also OMIM entry 150330].
The main mutation involved in HGPS, G608G, is a de
novomutationoccurringonapaternalinheritedallele
in the majority of cases [194, 195, 205], although one
caseofsomaticmosaicisminanasymptomaticmother
carrying the G608G mutation, and transmitting pro-
Figure 2. LaminA-processingpathway. Pre-laminA mRNA is encodedby the laminA/C gene(lamin C is a shorter splicevariant lacking
the CAAX motif) It is translated by cytosolic ribosomes and then becomes farnesylated by the action of farnesyl transferase, providing it
with a hydrophobic anchor by which it associates with the cytosolic side of the rough endoplasmic reticulum membrane. Proteolytic
cleavage of the two aliphatic and adjacent residue of the CAAX motif leaves pre-lamin A with a farnesylated cysteine residue. Further
cleavage by the Zmpste24 protease releases mature lamin A protein into the cytosol, from where it is transported into the nucleus. Once
inside the nucleus, lamin A can associate with membrane-bound lamin B to form the nuclear lamina, or it can remain soluble in the
nucleoplasm. Experimental or therapeutic interventions to relieve accumulation of pre-lamin A are shown in green, whilst deleterious
impacts on the pathways (naturally occurring or experimentally induced mutations) are shown in red.
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evidence that accumulated farnesylated prelamin A
(progerin) exerts toxic effects [210], suggesting that
only one mutant allele is required to cause disease.
Expression of progerin in the presence of wild-type
lamin A impacts significantly on the structure and
organisation of the nucleus [211], consistent with a
dominant negative action disrupting normal lamin
processing, assembly and turnover. Similarly, hetero-
zygous Lmna
HG/+ mice show HGPS-like cellular
defects [212]. These findings all support the conten-
tion that the common HGPS mutation (G608G)
exerts a dominant effect. However, compound heter-
ozygous mutations have also been reported [213],
which may result in atypical HGPS, and homozygous
mutation has been mooted to cause HGPS [214]. It is
noteworthy that some cases of the related laminop-
athy, neonatal lethal restrictive dermopathy (RD)
actually result from LMNA mutation [215–217;
reviewed in ref. 206], rather than the more usual
mutation in the Zmpste24 metalloprotease [216, 218].
It is possible that these may be more properly
considered as atypical, neonatal and severe progeria.
Moreover, syndromes in which Zmpste24 is mutant
show autosomal recessive inheritance.
Cellular phenotype in HGPS
HGPS cells show altered population dynamics, ab-
normal nuclear architecture and problems with DNA
replication, DNA repair and transcription as a con-
sequence of mutations in LMNA.
Abnormal nuclear morphology including deforma-
tion of the nuclear envelope and a loss of the usual
spherical shape of the nuclei is the major cellular
feature of the disease and is associated with the
appearance of micronuclei, where the genome has
been fragmented and recompartmentalised. Such
fragmented genomes are incapable of correct repli-
cation or segregation at mitosis, and may trigger
apoptosis. The fraction of cells with such abnormal
nuclear morphology increases as the population pro-
liferatesinculture,asdoestheproportion ofcellswith
a missing or abnormal A-type lamin [219], consistent
with the idea that such morphological abnormalities
arise as a consequence of cell replication and division.
Inadditiontoabnormal laminastaining,HGPSnuclei
show histone demethylation (specifically loss of
methyl-K9 on histone H3) and loss of the hetero-
chromatin protein HP1a [220], which contributes to
the observed loss of peripheral heterochromatin [221]
and further impacts on chromosome stability. Since
thenuclearlaminapenetratesthroughthenucleusand
provides a scaffold for DNA spooling during repli-
cation and transcription [222], loss of lamina integrity
can impact not only on nuclear structure but also on
nucleic acid processing. This is borne out by exper-
imental data demonstrating defects in DNA replica-
tion [223–225] and transcription [226, 227] in nuclei
with defective lamins. In addition, lamin A has been
proposed to recruit DNA repair proteins to sites of
damage, based on the aberrant distribution of Rad51
foci and the persistence of gH2AX foci in irradiated
HGPS cells compared with wild-type fibroblasts
[228].
In a mouse model of HGPS, which is null for the
Zmpste24 protease (hence with accumulation of wild-
type pre-lamin A), similar problems with Rad51
redistribution are observed, together with persistence
of damage foci [228]. Additionally, nuclear morphol-
ogy is aberrant in embryonic fibroblasts derived from
Zmpste24-null mice [229], similar to that observed in
mice null or mutant for Lmna [230].A high frequency
ofmicronucleiandlossofperipheralheterochromatin
is detected, entirely consistent with the phenotype
observed for HGPS patient fibroblasts. However,
there is no increase in apoptosis in the Zmpste24-null
mice[231],unliketheveryhighratesofcelldeathseen
in Lmna mutant mice [230]. The phenotypes in
Zmpste24 mutant mice were reversed by creation of
lamin A heterozygotes in an Zmpste24-null back-
ground [210], suggesting that at least in the presence
of mature lamin A, there is a threshold limit of pre-
lamin A that cells can tolerate before pathological
changes in nuclear architecture develop. However,
wild-type pre-lamin A and progerin may be differ-
entially toxic.
Consistent withhighlevelsofDNAdamageandother
stresses resulting from aberrant nuclear and chroma-
tin architecture, the p53 pathway appears to be
hyperactivated in HGPS cells [231]. Upregulation of
many p53 transcriptional targets including p21
CDKN1
and Gadd45 is observed, though oddly without
detectable increase in p53 protein or post-transla-
tional modification of p53 usually associated with
DNA damage responses [231]. Most notably, many of
the HGPS phenotypes are fully rescued by a decrease
in lamin A (i.e. Lmna+/-) and partially rescued by
deletion of p53; double-knockout p53-/- Lmna-/-
mouse cells proliferate more readily than single
knockdowns and show a normal nuclear morphology,
while the lifespan of the mice is extended [231]. This
resultisstronglysuggestivethatp53oritsdownstream
effectors such as p21 drive the senescence of HGPS
cells. Cultures of fibroblasts from some HGPS pa-
tients show a reduced proliferative capacity, with
aberrant population dynamics. However, rather than
the very rapid rates of exit from the cell cycle into
senescence seen in WS, HGPS cells show a hyerpro-
liferative phenotype in conjunction with high rates of
apoptosis [219].
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progerin has three profound consequences: (i) loss of
nuclear integrity and architecture, leading to changes
in chromatin structure and aberrant gene expression;
(ii) frank and persistent DNA damage resulting from
both aberrant sequestration by progerin of essential
repair proteins (e.g. Rad51) and lack of targeting of
such proteins by mature lamin A to sites of damage;
(iii) elevated rates of cell turnover driven primarily by
apoptosis. How do these features of the mutation link
to the progeroid features of the patient?
Our own view is that the fundamental nuclear
instability at the level of individual cells leads to
elevated rates of cellular apoptosis. These elevated
rates of cellular apoptosis lead to increased rates of
cell turnover within a population of HGPS cells. Such
increased rates of turnover generate increased num-
bers of senescent cells, which probably mediate much
of the pathology. In this sense, HGPS would be
analogous to WS at the cell population level but with
elevated senescent production being driven by a
failureto retaincellsrather thanan elevatedtendency
to enter the senescent state.
Impact of defects in lamin A processing on tissues and
cells
Abnormal fat metabolism is a clinically significant
feature of HGPS,with atherosclerosis leading to early
morbidity and mortality. By analogy to a related
laminopathy, Dunnigan-type familial partial lipodys-
trophy [232], we suggest that the abnormalities in fat
metabolism in HGPS may be caused by progerin
binding to and sequestering SREBP1 (Fig. 3), an
adipogenic transcription factor important in fat me-
tabolism and adipose differentiation. In normal adi-
pose differentiation, intranuclear SREBP1 binds and
activates the transcription factor PPARg [233];i t i s
possible that this does not occur adequately in HGPS,
and that the characteristic lipodystrophy is a conse-
quence of such sequestration of important transcrip-
tion factors. Lipodystrophy is a common feature in
many laminopathies, but structural differences in the
molecular conformation and stability of mutant
lamins in other laminopathies [234] suggest that the
causativemechanismmaydifferineach–forexample,
Dunnigan-type familial partial lipodystrophy results
from a stable lamin A that can no longer form
appropriate protein associations [234], though later
studies have shown the presence of peripheral pre-
lamin A in this syndrome [232]; whether protein-
protein interactions are similarly aberrant for proger-
in is less clear.
From genotype and phenotype to therapy in HGPS
A-type lamins are differentially expressed in human
cells [196], so it is possible that therapies directed at
HGPS could aim to decrease overall levels of LMNA
without deleterious effects. To this end, lentiviral
expression of short hairpin RNAi (shRNAi) targeted
against pre-spliced and mutant LMNA mRNA has
been carried out in HGPS fibroblasts [235]. This
treatment led to significant decreases in SA-b-gal
staining (a marker of senescent cells). Moreover, such
cells showed marked increases in proliferative capaci-
ty determined both by clonogenic assays and cumu-
lative population doublings. Most surprisingly, these
cells showed reversion of nuclear morphology to a
more rounded and regular appearance, with loss of
micronuclei, even though they are significantly lack-
ing in full length and D50 lamin A/progerin [235].
These authors suggest that shRNAi may be useful as a
tool in restricting arterial wall stenosis and thus
eventually be employed as gene therapy for HGPS
oncebetterdeliverysystemstargetingthearterialwall
have been developed [235]. This is obviously of huge
importance given that the major cause of death in
HGPS is from coronary artery atherosclerosis, and
deserves rapid follow-up.
Whilst RNAi has significant potential for in vivo
therapy, morpholinos (modified oligonucleotides)
have been reported to cause fewer  off-target  effects
in gene expression knock down studies. Morpholinos
targetedtothecrypticsplicesiteofprogerinhavebeen
usedsuccessfullytoreversephenotypesinHGPScells
including nuclear morphology, lamin A levels and
distribution, heterochromatin distribution and tran-
scription [220]. This is a proof of principle that
deserves rapid translation into the clinic.
Since gene delivery systems and in vivo gene therapy
in humans are still in their infancy, alternative
strategies are necessary if HGPS is to be treated in
any meaningful way in the near future. The loss of
heterochromatinobservedinHGPShasbeentargeted
byuseofthehistonedeacetylaseinhibitortrichostatin
A;togetherwithmevinolin,thiswas found notonly to
lead to restoration of heterochromatin organisation,
but also to reduce progerin levels markedly [221].
Such drugs therefore provide important new leads for
development of therapies for HGPS.
Themostpromisingofcurrentpossibletherapiesisthe
use of farnesyl transferase inhibitors to prevent the
formation of farnesylated pre-lamin A, a step that
normally targets pre-lamin A to the nuclear envelope
(see Fig. 2). The rationale is based on the assumption
that abnormalities in nuclear architecture and nuclear
blebbing resulting from incorporation of abnormal
pre-lamin A are causative of the pathology in HGPS.
This is based on data from HeLa cells bearing
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not be farnesylated, or farnesylated lamin A that
could not be cleaved [236]. Nuclei appeared morpho-
logically normal without lamin A, but HGPS-like
aberrant architecture was observed in cells expressing
the uncleavable variant [236]. Thus it is the presence
of progerin rather than the absence of lamin A that is
important in abnormal nuclear structure in HGPS.
Although FTIs would also interfere with isoprenyla-
tionofB-typelamins(andpossiblyotherproteinssuch
as c-ras), it was felt that this would be less deleterious
than accumulation of incorrectly processed lamin A.
To test this hypothesis, a mouse model of HGPS was
createdbygenetargetingtoproduceanLmna
HGallele
that encodes progerin [212, 237]. Embryonic fibro-
blasts from such mice showed nuclear blebbing and
abnormal lamin staining characteristic of HGPS,
together with high levels of progerin. Upon treatment
with the farnesyl transferase inhibitor PB-43, there
was a very marked decrease in nuclear blebbing in the
HG mouse fibroblasts [212], and improved growth
and bone structure in the mice [237]. Whilst these
Figure 3. Drivers of senescence and therapeutic opportunities in WS and HGPs. Drivers, factors leading to the accumulation of DNA
damage,areboxedatthetopofthediagram,withcausativefactorsshowninred.AllresultinDNAdamageifunchecked;however,several
therapeutic or modulatory options are now available. Blocking pre-lamin A farnesylation with farnesyl transferase inhibitors (FTIs), or
depleting lamin A using either morpholinos or RNAi leads to a significant reduction in aberrant morphological changes of the nucleus
usually associated with HGPS, and a reduction in resultant DNA damage. Mouse cells and mice models of HGPS treated with FTIs show
significant improvement in proliferation, and the entrie organism shows better bone structure and increased longevity. FTIs are already
licensed for treatment ofmalaria and variouscancers. Statins also reducefarnesylationand may prove usefulin HGPS. Telomereattrition
leading to signalling into the DNA damage pathway can be overcome in cell cultures by ectopically supplying telomerase, whilst the
problems with DNA replication and cell proliferation resulting from loss of WRN can be overcome using a Holliday junction resolving
enzyme, resolvase. As far as Signal transduction is concerned, during adipose differentiation, SRBEP1 binds and stimulates the PPARg
transcription factor; SREBP1 sequestration by progerin may prevent this in HGPS. Use of the PPARg agonist pioglitazone has proven
valuableindiminishingseveralaspectsoflipodystrophyandmetabolicsyndromeinWSpatientsandmayplayanequallyimportantrolein
the treatmentof HGPS. Once DNA damagehas occurred,throughwhatever route, there is still scope to modulatethe response ofthe cell
byinhibitingthestresssignaltransducingkinasep38with theinhibitorSB203580,adrugalreadylicensedforuse indiabetes.Movingonto
effectors;inhibitionofthetumoursuppressorp53maynotbeidealasitwouldbeexpectedtoleadtoincreaseincancerincidence;however,
interfering with its downstream effector p21
CDKN1 appears to reduce excess cell cycle exit and senescence in mouse models, without
increasing cancer incidence. Gene deletion in people is not yet a viable option as in experimental animals, but RNAi may prove useful in
this context. The flip side of preventing senescence using drugs is the possibility of causing senescence by design, with major benefits in
cancertherapy.Inparticular,hyperactivatingthep21
CDKN1pathwaythroughsmall-moleculedrugs(e.g.nucleosideanalogueCYC102)may
prove a fruitful therapeutic route.
Cell.Mol.Life Sci. Vol.64, 2007 Review Article 2633studies were conducted in a mouse model, there is
clear hope that FTIs will prove of benefit to HGPS
patients. As drugs, they are already approved for use
in treating malaria and cancers such as ductal breast
carcinomas.Intermsoftreatingverysickchildren,itis
also fortunate that FTIs are stable and can be given
orally, with generally good tolerance. Given the
severity and inevitable lethality of the condition,
fast-track approval of FTIs for clinical trials in HGPS
patients is a vital goal.
Conclusions
The last decade has produced an exponential rise in
our understanding of the molecular pathology of both
WS and HGPs. This growth in our understanding of
the disorders has also driven the development of
potential therapies which deserve to enter clinical
trials in the near future. The relationship between
disease mechanisms and routes to therapy is shown in
Figure 3. The successful treatment of a human
premature ageing syndrome by any of these means
would represent a tremendous medical advance.
Our knowledge of the pathology of these progeroid
syndromes may very well also bring benefits outside
the immediate arena of disease treatment. In this
review we have tried to show that there is a solid body
of data suggesting that the accumulation of senescent
cells is critical to many of the primary premature-
ageing phenotypes seen in WS and HGPS. This is an
important step in our understanding of the normal
ageing process itself, because at the time the disorders
were selected as useful potential ageing models,
virtually nothing was known about how the mutations
causing each disorder resultedin the phenotype of the
patients. In the case of HGPS, even the mode of
inheritance of the disease was the subject of intense
debate. Both WS and HGPS could, in principle, have
been caused by a very wide variety of mechanisms
which had no relevance to normal ageing. However it
isnowclearthatthemostlikelycauseoftheprogeroid
phenotype in both types of disorder is cell senescence,
a mechanism that was independently proposed to
cause ageing in normal individuals. Thus, if we can
successfully treat the premature-ageing diseases, it is
at least possible that we can ameliorate some aspects
of normal ageing as well. This is an exciting prospect.
Acknowledgements. We are grateful to the BBSRC for financial
support (grant numbers ERA16310 and BB/E000924/1 to LSC).
1 Lutz, W., Sanderson, W., and Scherbov, S. (1997) Doublingof
world population unlikely. Nature 387, 803 – 805.
2 Mills, H. (1998) Fit for the future: the prevention of depend-
ency in later life. Report of the Continuing Care Conference,
London (Prophet, H., Ed.).
3 Butcher, S. K. and Lord, J. M. (2004) Stress responses and
innate immunity: agingas a contributoryfactor.Aging Cell 3,
151 – 160.
4 Butcher,S. K.,Killampalli,V.,Lascelles,D.,Wang,K.,Alpar,
E. K., and Lord, J. M. (2005) Raised cortisol:DHEAS ratios
in the elderly after injury: potential impact upon neutrophil
function and immunity. Aging Cell 4, 319 – 324.
5 Pawelec, G. (2006) Immunity and ageing in man. Exp.
Gerontol. 41, 1239 – 1242.
6 Medawar, P. B., An unsolved problem of biology. Lewis,
London.
7 Kirkwood, T. B. (1996) Human senescence. Bioessays 18,
1009 – 1016.
8 Partridge, L. and Gems, D. (2002) The evolution of longevity.
Curr. Biol. 12, R544 – 546.
9 Chapman, T., Liddle, L. F., Kalb, J. M., Wolfner, M. F., and
Partridge,L.(1995)CostofmatinginDrosophilamelanogast-
er females is mediated by male accessory gland products.
Nature 373, 241 – 244.
10 Herndon,L. A.,Schmeissner,P. J.,Dudaronek,J. M.,Brown,
P. A.,Listner,K. M.,Sakano,Y.,Paupard,M. C.,Hall,D. H.,
and Driscoll, M. (2002) Stochastic and genetic factors
influence tissue-specific decline in ageing C. elegans. Nature
419, 808 – 814.
11 Martin, G. M. (1982) Syndromes of accelerated aging. Natl.
Cancer Inst. Monogr. 60, 241 – 247.
12 Kimura, K. D., Tissenbaum, H. A., Liu, Y., and Ruvkun, G.
(1997) daf-2, an insulin receptor-like gene that regulates
longevity and diapause in Caenorhabditis elegans. Science
277, 942 – 946.
13 Clancy, D. J., Gems, D., Harshman, L. G., Oldham, S.,
Stocker, H., Hafen, E., Leevers, S. J., and Partridge, L.
(2001) Extensionof life-span by loss of CHICO, a Drosophila
insulin receptor substrate protein. Science 292, 104 – 106.
14 Harper,J. M.,Salmon,A. B.,Leiser,S. F.,Galecki,A. T.,and
Miller, R. A. (2007) Skin-derived fibroblasts from long-lived
species are resistant to some, but not all, lethal stresses and to
the mitochondrial inhibitor rotenone. Aging Cell 6, 1 – 13.
15 Andziak, B. and Buffenstein, R. (2006) Disparate patterns of
age-related changes in lipid peroxidation in long-lived naked
mole-rats and shorter-lived mice. Aging Cell 5, 525 – 532.
16 Martin, G. M. (1985) Genetics and aging: the Werner
syndrome as a segmental progeroid syndrome. Adv. Exp.
Med. Biol. 190, 161 – 170.
17 Martin, G. M. (1997) The Werner mutation: does it lead to a
 public  or  private  mechanism of aging? Mol. Med. 3, 356 –
358.
18 Martin, G. M. (2005) Genetic modulation of senescent
phenotypes in Homo sapiens. Cell 120, 523 – 532.
19 Hayflick, L. (1965) The limited in vitro lifetime of human
diploid cell strains. Exp. Cell Res. 37, 614 – 636.
20 Shelton, D. N., Chang, E., Whittier, P. S., Choi, D., and Funk,
W. D. (1999) Microarray analysis of replicative senescence.
Curr. Biol. 9, 939 – 945.
21 Doggett, D. L., Rotenberg, M. O., Pignolo, R. J., Phillips,
P. D., and Cristofalo, V. J. (1992) Differential gene expression
between young and senescent, quiescent WI-38 cells. Mech.
Ageing Dev. 65, 239 – 255.
22 James, C. G., Appleton, C. T., Ulici, V., Underhill, T. M., and
Beier, F. (2005) Microarray analyses of gene expression
duringchondrocytedifferentiationidentifiesnovelregulators
of hypertrophy. Mol. Biol. Cell 16, 5316 – 5333.
23 Norsgaard, H., Clark, B. F., and Rattan, S. I. (1996) Distinc-
tion between differentiation and senescence and the absence
of increased apoptosis in human keratinocytes undergoing
cellular aging in vitro. Exp. Gerontol. 31, 563 – 570.
24 Adams, J. C. and Watt, F. M. (1988) An unusual strain of
human keratinocytes which do not stratify or undergo
2634 L. S. Cox and R. G. A. Faragher Progeroid syndromes: biology and therapyterminal differentiation in culture. J. Cell Biol. 107, 1927 –
1938.
25 Jones, R. B., Whitney, R. G., and Smith, J. R. (1985) Intra-
mitotic variation in proliferative potential: stochastic events
in cellular aging. Mech. Ageing Dev. 29, 143 – 149.
26 Smith,J. R.andWhitney,R. G.(1980)Intraclonalvariationin
proliferative potential of human diploid fibroblasts: stochas-
tic mechanism for cellular aging. Science 207, 82 – 84.
27 Ponten, J., Stein, W. D., and Shall, S. (1983) A quantitative
analysis of the aging of human glial cells in culture. J. Cell
Physiol. 117, 342 – 352.
28 Thomas,E.,alBaker,E.,Dropcova,S.,Denyer,S.,Ostad,N.,
Lloyd, A., Kill, I. R., and Faragher, R. G. (1997) Different
kinetics of senescence in human fibroblasts and peritoneal
mesothelial cells. Exp. Cell Res. 236, 355 – 358.
29 Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G.,
Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I.,
Pereira-Smith, O. Peacocke, M. and Campisi, J. (1995) A
biomarkerthatidentifiessenescenthumancellsincultureand
in aging skin in vivo. Proc. Natl. Acad. Sci. USA, 92, 9363 –
9367.
30 Minamino, T., Miyauchi, H., Yoshida, T., Tateno, K.,
Kunieda, T., and Komuro, I. (2004) Vascular cell senescence
and vascular aging. J. Mol. Cell. Cardiol. 36, 175 – 183.
31 Li, Y., Yan, Q., and Wolf, N. S. (1997) Long-term caloric
restrictiondelaysage-relateddeclineinproliferationcapacity
of murine lens epithelial cells in vitro and in vivo. Invest
Ophthalmol Vis. Sci. 38, 100 – 107.
32 Herbig, U., Ferreira, M., Condel, L., Carey, D., and Sedivy,
J. M. (2006) Cellular senescence in aging primates. Science
311, 1257.
33 Jeyapalan, J. C., Ferreira, M., Sedivy, J. M., and Herbig, U.
(2007) Accumulation of senescent cells in mitotic tissue of
aging primates. Mech. Ageing Dev. 128, 36 – 44.
34 Krtolica, A., Parrinello, S., Lockett, S., Desprez, P. Y., and
Campisi, J. (2001) Senescent fibroblasts promote epithelial
cell growth and tumorigenesis: a link between cancer and
aging. Proc. Natl. Acad. Sci. USA 98, 12072 – 12077.
35 Martin, G. M., Sprague, C. A., and Epstein, C. J. (1970)
Replicative life-span of cultivated human cells: effects of
donor s age, tissue, and genotype. Lab. Invest. 23, 86 – 92.
36 Goldstein,S., Moerman,E. J., Soeldner, J. S., Gleason,R. E.,
and Barnett, D. M. (1978) Chronologic and physiologic age
affect replicative life-span of fibroblasts from diabetic,
prediabetic, and normal donors. Science 199, 781 – 782.
37 Cristofalo, V. J., Allen, R. G., Pignolo, R. J., Martin, B. G.,
and Beck, J. C. (1998) Relationship between donor age and
the replicative lifespan of human cells in culture: a reevalua-
tion. Proc. Natl. Acad. Sci. USA 95, 10614 – 10619.
38 Maier, A. B., le Cessie, S., de Koning-Treurniet, C., Blom, J.,
Westendorp, R. G., and van Heemst, D. (2007) Persistence of
high-replicative capacity in cultured fibroblasts from non-
agenarians. Aging Cell 6, 27 – 33.
39 Funk, W. D., Wang, C. K., Shelton, D. N., Harley, C. B.,
Pagon, G. D., and Hoeffler, W. K. (2000) Telomerase expres-
sion restores dermal integrity to in vitro-aged fibroblasts in a
reconstituted skin model. Exp. Cell Res. 258, 270 – 278.
40 Minamino,T.,Yoshida,T.,Tateno,K.,Miyauchi,H.,Zou,Y.,
Toko, H.,and Komuro,I. (2003)Rasinducesvascularsmooth
muscle cell senescence and inflammation in human athero-
sclerosis. Circulation 108, 2264 – 2269.
41 DePinho, R. A. and Wong, K. K. (2003) The age of cancer:
telomeres,checkpoints,andlongevity.J.Clin.Invest.111,S9 –
14.
42 Campisi, J. (2001) Cellular senescence as a tumor-suppressor
mechanism. Trends Cell Biol. 11, S27 – 31.
43 Beausejour, C. M. and Campisi, J. (2006) Ageing: balancing
regeneration and cancer. Nature 443, 404 – 405.
44 Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., and
Lowe, S. W. (1997) Oncogenic ras provokes premature cell
senescence associated with accumulation of p53 and
p16INK4a. Cell 88, 593 – 602.
45 Mouton, R. E. and Venable, M. E. (2000) Ceramide induces
expression of the senescence histochemical marker, beta-
galactosidase, in human fibroblasts. Mech. Ageing Dev. 113,
169 – 181.
46 Tyner, S. D., Venkatachalam, S., Choi, J., Jones, S., Ghebra-
nious, N., Igelmann, H., Lu, X., Soron, G., Cooper, B.,
Brayton, C., Hee Park, S., Thompson, T., Karsenty, G.,
Bradley, A., and Donehower, L. A. (2002) p53 mutant mice
that display early ageing-associated phenotypes. Nature 415,
45 – 53.
47 Jacobs, J. J. and de Lange, T. (2004) Significant role for
p16INK4ain p53-independenttelomere-directed senescence.
Curr. Biol. 14, 2302 – 2308.
48 Davis, T., Singhrao, S. K., Wyllie, F. S., Haughton, M. F.,
Smith, P. J., Wiltshire, M., Wynford-Thomas, D., Jones, C. J.,
Faragher, R. G., and Kipling, D. (2003) Telomere-based
proliferativelifespanbarriersinWerner-syndromefibroblasts
involve both p53-dependent and p53-independent mecha-
nisms. J. Cell Sci. 116, 1349 – 1357.
49 Dickson, M. A., Hahn, W. C., Ino, Y., Ronfard, V., Wu, J. Y.,
Weinberg, R. A., Louis, D. N., Li, F. P., and Rheinwald, J. G.
(2000) Human keratinocytes that express hTERT and also
bypass a p16(INK4a)-enforced mechanism that limits life
span become immortal yet retain normal growth and differ-
entiation characteristics. Mol Cell Biol 20, 1436 – 1447.
50 El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B.,
Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler,
K. W.,andVogelstein,B.(1993)WAF-1,a potentialmediator
of p53 tumour suppression. Cell 75, 817 – 825.
51 Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and
Elledge, S. J. (1993)The p21Cdk-interacting proteinCip1 is a
potent inhibitor of G1 cyclin-dependent kinases. Cell 75,
805 – 816.
52 Noda, A., Ning, Y., Venable, S. F., Pereira Smith, O. M., and
Smith, J. R. (1994) Cloning of senescent cell-derived inhib-
itors of DNA synthesis using an expression screen. Exp. Cell
Res. 211, 90 – 98.
53 Evans, R. J., Wyllie, F. S., Wynford-Thomas, D., Kipling, D.,
andJones, C. J. (2003)A P53-dependent, telomere-independ-
ent proliferative life span barrier in human astrocytes
consistent with the molecular genetics of glioma develop-
ment. Cancer Res. 63, 4854 – 4861.
54 Sharpless, N. E. and DePinho, R. A. (2007) Cancer biology:
gone but not forgotten. Nature 445, 606 – 607.
55 Rudolph, K. L., Chang, S., Lee, H. W., Blasco, M., Gottlieb,
G. J.,Greider,C.,andDePinho,R. A.(1999)Longevity,stress
response, and cancer in aging telomerase-deficient mice. Cell
96, 701 – 712.
56 Chin, L., Artandi, S. E., Shen, Q., Tam, A., Lee, S. L.,
Gottlieb,G. J.,Greider,C. W.,andDePinho,R. A.(1999)p53
deficiency rescues the adverse effects of telomere loss and
cooperates with telomere dysfunction to accelerate carcino-
genesis. Cell 97, 527 – 538.
57 Choudhury,A. R.,Ju,Z.,Djojosubroto,M. W.,Schienke, A.,
Lechel,A., Schaetzlein,S., Jiang,H., Stepczynska,A., Wang,
C., Buer, J., Lee, H. W., von Zglinicki, T., Ganser, A.,
Schirmacher, P., Nakauchi, H., and Rudolph, K. L. (2007)
Cdkn1a deletion improves stem cell function and lifespan of
mice with dysfunctional telomeres without accelerating
cancer formation. Nat. Genet. 39, 99 – 105.
58 Werner, C. W.O. (1904)  ber Katarakt in Verbindung mit
Sklerodermie. PhD thesis, University of Kiel. Schmidt and
Klaunig, Kiel.
59 Goto, M. (2001) Clinical characteristics of Werner syndrome
and other premature aging syndromes: pattern of aging in
progeroid syndromes. In: From Premature Gray Hair to
Helicase-Werner Syndrome: Implications for Aging and
Cancer, p. 27 – 39. Goto, M. and. Miller, R. W (Eds.), Japan
Scientific Societies Press, Tokyo.
60 Anderson, N. E. and Haas, L. F. (2003) Neurological compli-
cations of Werner s syndrome. J. Neurol. 250, 1174 – 1178.
Cell.Mol.Life Sci. Vol.64, 2007 Review Article 263561 Goto,M.(1997)Hierarchicaldeteriorationofbodysystemsin
Werner s syndrome: implications for normal ageing. Mech.
Ageing Dev. 98, 239 – 254.
62 Epstein, C. J., Martin, G. M., Schultz, A. L., and Motulsky,
A. G. (1966) Werner s syndrome: a review of its symptoma-
tology, natural history, pathologic features, genetics and
relationship to the natural aging process. Medicine (Balti-
more) 45, 177 – 221.
63 Payao, S. L., de Labio, R. W., Gatti, L. L., Rigolin, V. O.,
Bertolucci, P. H., and Smith Mde, A. (2004) Werner helicase
polymorphism is not associated with Alzheimer s disease.
J. Alzheimers Dis. 6, 591 – 594.
64 Goto, M. and Miller, R. W. (Eds.) (2001) From Premature
Gray Hair to Helicase-Werner Syndrome: Implications for
Aging and Cancer. Japan Scientific Societies Press,
Tokyo. 178.
65 Huang, S., Lee, L., Hanson, N. B., Lenaerts, C., Hoehn, H.,
Poot, M., Rubin, C. D., Chen, D. F., Yang, C. C., Juch, H.,
Dorn, T., Spiegel, R. et al. (2006) The spectrum of WRN
mutations in Werner syndrome patients. Hum. Mutat. 27,
558 – 567.
66 Yu, C. E., Oshima, J., Goddard, K. A., Miki, T., Nakura, J.,
Ogihara, T., Poot, M., Hoehn, H., Fraccaro, M., Piussan, C.,
Martin,G.M.,Schellenberg,G.D.andWijsman,E.M.(1994)
Linkagedisequilibriumandhaplotypestudiesofchromosome
8p 11.1 – 21.1 markers and Werner syndrome. Am. J. Hum.
Genet. 55, 356 – 364.
67 Imbert,A.,Chaffanet,M.,Essioux,L.,Noguchi,T.,Adelaide,
J., Kerangueven, F., Le Paslier, D., Bonaiti-Pellie, C., Sobol,
H.,Birnbaum,D.,andPebusque,M. J.(1996)Integratedmap
of the chromosome 8p12-p21 region, a region involved in
human cancers and Werner syndrome. Genomics 32, 29 – 38.
68 Yu, C. E., Oshima, J., Fu, Y. H., Wijsman, E. M., Hisama, F.,
Alisch, R., Matthews, S., Nakura, J., Miki, T., Ouais, S.,
Martin, G. M., Mulligan, J., and Schellenberg, G. D. (1996)
Positional cloning of the Werner s syndrome gene. Science
272, 258 – 262.
69 Bachrati, C. Z. and Hickson, I. D. (2003) RecQ helicases:
suppressors of tumorigenesis and premature aging. Biochem.
J. 374, 577 – 606.
70 Cordin,O.,Banroques,J.,Tanner,N. K.,andLinder,P.(2006)
The DEAD-box protein family of RNA helicases. Gene 367,
17 – 37.
71 Gray, M. D., Shen, J. C., Kamath-Loeb, A. S., Blank, A.,
Sopher, B. L., Martin, G. M., Oshima, J., and Loeb, L. A.
(1997) The Werner syndrome protein is a DNA helicase. Nat.
Genet. 17, 100 – 103.
72 Huang, S., Li, B., Gray, M. D., Oshima, J., Mian, I. S., and
Campisi, J. (1998) The premature ageing syndrome protein,
WRN, is a 3 -5  exonuclease. Nat. Genet. 20, 114 – 116.
73 Matsumoto, T., Imamura, O., Goto, M., and Furuichi, Y.
(1998) Characterization of the nuclear localization signal in
the DNA helicaseinvolvedin Werner s syndrome. Int. J. Mol.
Med. 1, 71 – 76.
74 von Kobbe, C. and Bohr, V. A. (2002) A nucleolar targeting
sequence in the Werner syndrome protein resides within
residues 949 – 1092. J. Cell Sci. 115, 3901 – 3907.
75 Suzuki, T., Shiratori, M., Furuichi, Y., and Matsumoto, T.
(2001) Diverged nuclear localization of Werner helicase in
human and mouse cells. Oncogene 20, 2551 – 2558.
76 Marciniak, R. A., Lombard, D. B., Johnson, F. B., and
Guarente, L. (1998) Nucleolar localization of the Werner
syndrome protein in human cells. Proc. Natl. Acad. Sci. USA
95, 6887 – 6892.
77 Bohr, V. A. (2005) Deficient DNA repair in the human
progeroiddisorder,Wernersyndrome.Mutat.Res.577,252 –
259.
78 Moser, M. J., Oshima, J., and Monnat, R. J., Jr. (1999) WRN
mutations in Werner syndrome. Hum. Mutat. 13, 271 – 279.
79 Kashino, G., Kodama, S., Suzuki, K., Oshimura, M., and
Watanabe, M. (2001) Preferential expression of an intact
WRN gene in Werner syndrome cell lines in which a normal
chromosome 8 has been introduced. Biochem. Biophys. Res.
Commun. 289, 111 – 115.
80 Moser,M. J.,Kamath-Loeb,A. S.,Jacob,J. E.,Bennett,S. E.,
Oshima, J., and Monnat, R. J., Jr. (2000) WRN helicase
expression in Werner syndrome cell lines. Nucleic Acids Res.
28, 648 – 654.
81 Killoran, M. P. and Keck, J. L. (2006) Sit down, relax and
unwind: structural insights into RecQ helicase mechanisms.
Nucleic Acids Res. 34, 4098 – 4105.
82 Kamath-Loeb,A. S.,Welcsh,P.,Waite,M.,Adman,E. T.,and
Loeb, L. A. (2004) The enzymatic activities of the Werner
syndrome protein are disabled by the amino acid polymor-
phism R834C. J. Biol. Chem. 279, 55499 – 55505.
83 Castro, E., Edland, S. D., Lee, L., Ogburn, C. E., Deeb, S. S.,
Brown, G., Panduro, A., Riestra, R., Tilvis, R., Louhija, J.,
Penttinen, R., Erkkola, R., Wang, L., Martin, G. M., and
Oshima, J. (2000) Polymorphisms at the Werner locus.
II. 1074Leu/Phe, 1367Cys/Arg,longevity, and atherosclerosis.
Am. J. Med. Genet. 95, 374 – 380.
84 Passarino, G., Shen, P., Van Kirk, J. B., Lin, A. A., De
Benedictis, G., CavalliSforza,L. L., Oefner, P. J., and Under-
hill, P. A. (2001) The Werner syndrome gene and global
sequence variation. Genomics 71, 118 – 122.
85 Smith, M. A., Silva, M. D., Araujo, L. Q., Ramos, L. R.,
Labio, R. W., Burbano, R. R., Peres, C. A., Andreoli, S. B.,
Payao, S. L., and Cendoroglo, M. S. (2005) Frequency of
Werner helicase 1367 polymorphism and age-related morbid-
ity in an elderly Brazilian population. Braz. J. Med. Biol. Res.
38, 1053 – 1059.
86 Castro, E., Ogburn, C. E., Hunt, K. E., Tilvis, R., Louhija, J.,
Penttinen, R.,Erkkola,R.,Panduro,A.,Riestra,R.,Piussan,
C., Deeb, S. S., Wang, L. et al. (1999) Polymorphisms at the
Werner locus: I. Newly identified polymorphisms, ethnic
variability of 1367Cy/Arg, and its stability in a population of
Finnish centenarians. Am. J. Med. Genet. 82, 399 – 403.
87 Ye, L., Miki, T., Nakura, J., Oshima, J., Kamino, K., Rakugi,
H., Ikegami, H., Higaki, J., Edland, S. D., Martin, G. M., and
Ogihara,T.(1997)Associationofapolymorphicvariantofthe
WernerhelicasegenewithmyocardialinfarctioninaJapanese
population[publishederratumappearsinAm.J.Med.Genet.
1997 May 2;70(1),103]. Am. J. Med. Genet. 68, 494 – 498.
88 Bohr,V. A.,Metter,E. J.,Harrigan,J. A.,vonKobbe,C.,Liu,
J. L., Gray, M. D., Majumdar, A., Wilson, D. M., 3rd, and
Seidman, M. M. (2004) Werner syndrome protein 1367
variants and disposition towards coronary artery disease in
Caucasian patients. Mech. Ageing Dev. 125, 491 – 496.
89 Brosh, R. M., Jr., Waheed, J., and Sommers, J. A. (2002)
Biochemical characterization of the DNA substrate specific-
ity of Werner syndrome helicase. J. Biol. Chem. 277, 23236 –
23245.
90 Salk, D., Au, K., Hoehn, H., and Martin, G. M. (1981)
Cytogenetics of Werner s syndrome cultured skin fibroblasts:
variegated translocation mosaicism. Cytogenet. Cell. Genet.
30, 92 – 107.
91 Scappaticci, S., Cerimele, D., and Fraccaro, M. (1982) Clonal
structuralchromosomalrearrangementsinprimaryfibroblast
cultures and in lymphocytes of patients with Werner s
Syndrome. Hum. Genet. 62, 16 – 24.
92 Fukuchi, K., Martin, G. M., and Monnat, R. J., Jr. (1989)
Mutator phenotype of Werner syndrome is characterized by
extensive deletions. Proc. Natl. Acad. Sci. USA 86, 5893 –
5897.
93 Agrelo, R., Cheng, W. H., Setien, F., Ropero, S., Espada, J.,
Fraga, M. F., Herranz, M., Paz, M. F., Sanchez-Cespedes, M.,
Artiga,M. J.,Guerrero,D.,Castells,A.,vonKobbe,C.,Bohr,
V. A., and Esteller, M. (2006) Epigenetic inactivation of the
premature aging Werner syndrome gene in human cancer.
Proc. Natl. Acad. Sci. USA 103, 8822 – 8827.
94 Lebel, M., Spillare, E. A., Harris, C. C., and Leder, P. (1999)
TheWernersyndromegeneproductco-purifieswiththeDNA
replication complex and interacts with PCNA and topoiso-
merase I. J. Biol. Chem. 274, 37795 – 37799.
2636 L. S. Cox and R. G. A. Faragher Progeroid syndromes: biology and therapy95 Cox, L. S. (1997) Who binds wins: PCNA rings out the cell
cycle changes. Trends in Cell Biol. 7, 493 – 498.
96 Warbrick, E. (1998) PCNA binding through a conserved
motif. Bioessays 20, 195 – 199.
97 Rodriguez-Lopez, A. M., Jackson, D. A., Nehlin, J. O., Ibor-
ra,F.,Warren,A. V.,andCox,L. S.(2003)Characterisationof
the interaction between WRN, the helicase/exonuclease
defective in progeroid Werner s syndrome, and an essential
replication factor, PCNA. Mech. Ageing Dev. 124, 167 – 174.
98 Brosh, R. M., Jr., von Kobbe, C., Sommers, J. A., Karmakar,
P., Opresko, P. L., Piotrowski, J., Dianova, I., Dianov, G. L.,
and Bohr, V. A. (2001) Werner syndrome protein interacts
with human flap endonuclease 1 and stimulates its cleavage
activity. EMBO J. 20, 5791 – 5801.
99 Sharma, S., Otterlei, M., Sommers, J. A., Driscoll, H. C.,
Dianov, G. L., Kao, H. I., Bambara, R. A., and Brosh, R. M.
Jr. (2004) WRN helicase and FEN-1 form a complex upon
replicationarrestandtogetherprocessbranchmigratingDNA
structuresassociated withthe replication fork.Mol.Biol.Cell
15, 734 – 750.
100 Kao, H. I. and Bambara, R. A. (2003) The protein compo-
nents and mechanism of eukaryotic Okazaki fragment
maturation. Crit. Rev. Biochem. Mol. Biol. 38, 433 – 452.
101 Brosh, R. M., Jr., Driscoll, H. C., Dianov, G. L., and Somm-
ers, J. A. (2002) Biochemical characterization of the WRN-
FEN-1 functional interaction. Biochemistry 41, 12204 –
12216.
102 Zheng, L., Zhou, M., Chai, Q., Parrish, J., Xue, D., Patrick,
S. M., Turchi, J. J., Yannone, S. M., Chen, D., and Shen, B.
(2005) Novel function of the flap endonuclease 1 complex in
processingstalledDNAreplicationforks.EMBORep.6,83 –
89.
103 Pichierri, P., Franchitto, A., Mosesso, P., and Palitti, F. (2001)
Werner s syndrome protein is required for correct recovery
after replication arrest and DNA damage induced in S-phase
of cell cycle. Mol. Biol. Cell. 12, 2412 – 2421.
104 Rodriguez-Lopez, A. M., Jackson, D. A., Iborra, F., and Cox,
L. S. (2002) Asymmetry of DNA replication fork progression
in Werner s syndrome. Aging Cell 1, 30 – 39.
105 Rodriguez-Lopez, A. M., Whitby, M. C., Borer, C. M., Bach-
ler, M. A., and Cox, L. S. (2007) Correction of proliferation
and drug sensitivity defects in the progeroid Werner s
syndrome by Holliday junction resolution. Rejuvenation
Res. 10, 27 – 40.
106 Sharma,S.,Sommers,J. A.,Gary,R. K.,Friedrich-Heineken,
E.,Hubscher,U.,andBrosh,R. M.,Jr.(2005)Theinteraction
site of Flap Endonuclease-1 with WRN helicase suggests a
coordination of WRN and PCNA. Nucleic Acids Res. 33,
6769 – 6781.
107 Constantinou, A., Tarsounas, M., Karow, J. K., Brosh, R. M.,
Bohr, V. A., Hickson, I. D., and West, S. C. (2000) Werner s
syndrome protein (WRN) migrates Holliday junctions and
co-localizeswith RPAupon replicationarrest.EMBO Rep. 1,
80 – 84.
108 Takeuchi, F., Hanaoka, F., Goto, M., Yamada, M., and
Miyamoto, T. (1982) Prolongation of S phase and whole cell
cycle in Werner s syndrome fibroblasts. Exp. Gerontol. 17,
473 – 480.
109 Poot,M.,Hoehn,H.,Runger,T. M.,andMartin,G. M.(1992)
Impaired S-phase transit of Werner syndrome cells expressed
in lymphoblastoid cell lines. Exp. Cell Res. 202, 267 – 273.
110 Griffiths, T. D. (1984) S-phase transit times as a function of
ageinhumandiploidfibroblasts.Mech.AgeingDev.24,273 –
282.
111 Fujiwara, Y., Higashikawa, T., and Tatsumi, M. (1977) A
retarded rate of DNA replication and normal level of DNA
repair in Werner s syndrome fibroblasts in culture. J. Cell
Physiol. 92, 365 – 374.
112 Takeuchi, F., Hanaoka, F., Goto, M., Akaoka, I., Hori, T.,
Yamada, M., and Miyamoto, T. (1982) Altered frequency of
initiationsitesofDNAreplicationinWerner ssyndromecells.
Hum. Genet. 60, 365 – 368.
113 Machwe, A., Xiao, L., Groden, J., and Orren, D. K. (2006)
The Werner and Bloom syndrome proteins catalyze regres-
sion of a model replication fork. Biochemistry 45, 13939 –
13946.
114 Pichierri,P.,Franchitto,A.,Mosesso,P.,ProiettideSantis,L.,
Balajee, A. S., and Palitti, F. (2000) Werner s syndrome
lymphoblastoid cells are hypersensitive to topoisomerase II
inhibitors in the G2 phase of the cell cycle. Mutat. Res. 459,
123 – 133.
115 Poot, M., Gollahon, K. A., and Rabinovitch, P. S. (1999)
Werner syndrome lymphoblastoid cells are sensitive to
camptothecin-induced apoptosis in S-phase. Hum. Genet.
104, 10 – 14.
116 Lowe,J.,Sheerin,A.,Jennert-Burston,K.,Burton,D.,Ostler,
E. L., Bird, J., Green, M. H., and Faragher, R. G. (2004)
Camptothecin sensitivity in Werner syndrome fibroblasts as
assessedbytheCOMETtechnique. Ann.NYAcad.Sci.1019,
256 – 259.
117 Shao,R. G.,Cao,C. X.,Zhang,H.,Kohn,K. W.,Wold,M. S.,
and Pommier, Y. (1999) Replication-mediated DNA damage
by camptothecin induces phosphorylation of RPA by DNA-
dependent protein kinase and dissociates RPA:DNA-PK
complexes. EMBO J. 18, 1397 – 1406.
118 Laine, J. P., Opresko, P. L., Indig, F. E., Harrigan, J. A., von
Kobbe, C., and Bohr, V. A. (2003) Werner protein stimulates
topoisomerase I DNA relaxation activity. Cancer Res. 63,
7136 – 7146.
119 Gerber, J. K., Gogel, E., Berger, C., Wallisch, M., Muller, F.,
Grummt, I., and Grummt, F. (1997) Termination of mamma-
lian rDNA replication: polar arrest of replication fork move-
mentbytranscriptionterminationfactorTTF-I.Cell90,559 –
567.
120 Caburet, S., Conti, C., Schurra, C., Lebofsky, R., Edelstein,
S. J., and Bensimon, A. (2005) Human ribosomal RNA gene
arrays display a broad range of palindromic structures.
Genome Res. 15, 1079 – 1085.
121 Sinclair,D. A.,Mills,K.,andGuarente,L.(1997)Accelerated
aging and nucleolar fragmentation in yeast sgs1 mutants.
Science 277, 1313 – 1316.
122 Sinclair, D. A. and Guarente, L. (1997) Extrachromosomal
rDNA circles–a cause of aging in yeast. Cell 91, 1033 – 1042.
123 Kamath-Loeb, A. S., Loeb, L. A., Johansson, E., Burgers,
P. M., and Fry, M. (2001) Interactions between the Werner
syndrome helicase and DNA polymerase delta specifically
facilitate copying of tetraplex and hairpin structures of the
d(CGG)n trinucleotide repeat sequence. J. Biol. Chem. 276,
16439 – 16446.
124 Orren, D. K., Theodore, S., and Machwe, A. (2002) The
Werner syndrome helicase/exonuclease (WRN) disrupts and
degrades D-loops in vitro. Biochemistry 41, 13483 – 13488.
125 Machwe, A., Xiao, L., and Orren, D. K. (2004) TRF2 recruits
the Werner syndrome (WRN) exonuclease for processing of
telomeric DNA. Oncogene 23, 149 – 156.
126 Opresko, P. L., von Kobbe, C., Laine, J. P., Harrigan, J.,
Hickson, I. D., and Bohr, V. A. (2002) Telomere-binding
protein TRF2 binds to and stimulates the Werner and Bloom
syndrome helicases. J. Biol. Chem. 277, 41110 – 41119.
127 Opresko, P. L., Otterlei, M., Graakjaer, J., Bruheim, P.,
Dawut, L., Kolvraa, S., May, A., Seidman, M. M., and Bohr,
V. A. (2004) The Werner syndrome helicase and exonuclease
cooperate toresolve telomeric D loops in a manner regulated
by TRF1 and TRF2. Mol. Cell 14, 763 – 774.
128 Crabbe, L., Verdun, R. E., Haggblom, C. I., and Karlseder, J.
(2004) Defective telomere lagging strand synthesis in cells
lacking WRN helicase activity. Science 306, 1951 – 1953.
129 Schulz, V. P., Zakian, V. A., Ogburn, C. E., McKay, J.,
Jarzebowicz, A. A., Edland, S. D., and Martin, G. M. (1996)
Accelerated loss of telomeric repeats may not explain
accelerated replicative decline of Werner syndrome cells.
Hum. Genet. 97, 750 – 754.
130 Tahara,H., Tokutake, Y., Maeda,S., Kataoka,H., Watanabe,
T., Satoh, M., Matsumoto, T., Sugawara, M., Ide, T., Goto,
Cell.Mol.Life Sci. Vol.64, 2007 Review Article 2637M., Furuichi, Y., and Sugimoto, M. (1997) Abnormal
telomere dynamics of B-lymphoblastoid cell strains from
Werner s syndrome patients transformed by Epstein-Barr
virus. Oncogene 15, 1911 – 1920.
131 Baird, D. M., Davis, T., Rowson, J., Jones, C. J., and Kipling,
D.(2004)Normaltelomereerosionratesatthesinglecelllevel
in Werner syndrome fibroblast cells. Hum. Mol. Genet. 13,
1515 – 1524.
132 Wyllie, F. S., Jones, C. J., Skinner, J. W., Haughton, M. F.,
Wallis, C., Wynford-Thomas, D., Faragher, R. G., and Kip-
ling, D. (2000) Telomerase prevents the accelerated cell
ageing of Werner syndrome fibroblasts. Nat. Genet. 24, 16 –
17.
133 Ostler,E. L.,Wallis,C. V.,Sheerin,A. N.,andFaragher,R. G.
(2002) A model for the phenotypic presentation of Werner s
syndrome. Exp. Gerontol. 37, 285 – 292.
134 Bird, J., Ostler, E. L., and Faragher, R. G. (2003) Can we say
that senescent cells cause ageing? Exp. Gerontol. 38, 1319 –
1326.
135 Ariyoshi, K., Kodama, S., and Watanabe, M. (in press)
Increased chromosome instability and accumulation of DNA
double-strand breaks in Werner syndrome cells. J. Radiat.
Res.
136 Crabbe, L., Jauch, A., Naeger, C. M., Holtgreve-Grez, H.,
and Karlseder, J. (2007) Telomere dysfunction as a cause of
genomic instability in Werner syndrome. Proc. Natl. Acad.
Sci. USA 104, 2205 – 2210.
137 Saintigny, Y., Makienko, K., Swanson, C., Emond, M. J., and
Monnat, R. J., Jr. (2002) Homologous recombination reso-
lution defect in werner syndrome. Mol. Cell Biol. 22, 6971 –
6978.
138 Baynton, K., Otterlei, M., Bjoras, M., von Kobbe, C., Bohr,
V. A., and Seeberg, E. (2003) WRN interacts physically and
functionally with the recombination mediator protein
RAD52. J. Biol. Chem. 278, 36476 – 36486.
139 Prince,P. R.,Emond,M. J.,andMonnat,R. J.,Jr.(2001)Loss
of Werner syndrome protein function promotes aberrant
mitotic recombination. Genes Dev. 15, 933 – 938.
140 Yamagata, K., Kato, J., Shimamoto, A., Goto, M., Furuichi,
Y., and Ikeda, H. (1998) Bloom s and Werner s syndrome
genes suppress hyperrecombination in yeast sgs1 mutant:
implication for genomic instability in human diseases. Proc.
Natl. Acad. Sci. USA 95, 8733 – 8738.
141 Stewart, E., Chapman, C. R., Al-Khodairy, F., Carr, A. M.,
andEnoch,T.(1997)rqh1+,afissionyeastgenerelatedtothe
Bloom s and Werner s syndrome genes, is required for
reversible S phase arrest. EMBO J. 16, 2682 – 2692.
142 Cheng, W. H., von Kobbe, C., Opresko, P. L., Arthur, L. M.,
Komatsu, K., Seidman, M. M., Carney, J. P., and Bohr, V. A.
(2004) Linkage between Werner syndrome protein and the
Mre11 complex via Nbs1. J. Biol. Chem. 279, 21169 – 21176.
143 Cheng, W. H., Sakamoto, S., Fox, J. T., Komatsu, K., Carney,
J., and Bohr, V. A. (2005) Werner syndrome protein asso-
ciates with gamma H2AX in a manner that depends upon
Nbs1. FEBS Lett. 579, 1350 – 1356.
144 Stravardi,E. S. and Halazonetis, T. D. (2005)Nbs1movingup
in the world. Nat. Cell Biol. 7, 648 – 650.
145 Plank, J. L., Wu, J., and Hsieh, T. S. (2006) Topoisomerase
IIIalpha and Bloom s helicase can resolve a mobile double
Holliday junction substrate through convergent branch
migration. Proc. Natl. Acad. Sci. USA 103, 11118 – 11123.
146 Raynard, S., Bussen, W., and Sung, P. (2006) A double
Holliday junction dissolvasome comprising BLM, topoiso-
meraseIIIalpha,andBLAP75.J.Biol.Chem.281(20),13861 –
13864.
147 Wu, L., Lung Chan, K., Ralf, C., Bernstein, D. A., Garcia,
P. L., Bohr, V. A., Vindigni, A., Janscak, P., Keck, J. L., and
Hickson, I. D. (2005) The HRDC domain of BLM is required
for the dissolution of double Holliday junctions. EMBO J. 24,
2679 – 2687.
148 Runger, T. M., Bauer,C., Dekant, B., Moller, K., Sobotta, P.,
Czerny,C.,Poot,M.,andMartin,G. M.(1994)Hypermutable
ligation of plasmid DNA ends in cells from patients with
Werner syndrome. J. Invest. Dermatol. 102, 45 – 48.
149 Oshima,J.,Huang,S.,Pae,C.,Campisi,J.,andSchiestl,R. H.
(2002) Lack of WRN results in extensive deletion at non-
homologous joining ends. Cancer Res. 62, 547 – 551.
150 Chen, L., Huang, S., Lee, L., Davalos, A., Schiestl, R. H.,
Campisi,J.,andOshima,J.(2003)WRN,theproteindeficient
in Werner syndrome, plays a critical structural role in
optimizing DNA repair. Aging Cell 2, 191 – 199.
151 Li, B., Navarro, S., Kasahara, N., and Comai, L. (2004)
Identificationandbiochemicalcharacterizationofa Werner s
syndrome protein complex with Ku70/80 and poly(ADP-
ribose) polymerase-1. J. Biol. Chem. 279, 13659 – 13667.
152 Perry, J. J., Yannone, S. M., Holden, L. G., Hitomi, C.,
Asaithamby, A., Han, S., Cooper, P. K., Chen, D. J., and
Tainer, J. A. (2006) WRN exonuclease structure and molec-
ularmechanismimplyaneditingroleinDNAendprocessing.
Nat. Struct. Mol. Biol. 13, 414 – 422.
153 Otsuki,M.,Seki,M.,Kawabe,Y.,Inoue,E.,Dong,Y. P.,Abe,
T.,Kato,G.,Yoshimura,A.,Tada,S.,andEnomoto,T.(2007)
WRN counteracts the NHEJ pathway upon camptothecin
exposure. Biochem. Biophys. Res. Commun. 355, 477 – 482.
154 Prince, P. R., Ogburn, C. E., Moser, M. J., Emond, M. J.,
Martin, G. M., and Monnat, R. J., Jr. (1999) Cell fusion
corrects the 4-nitroquinoline 1-oxide sensitivity of Werner
syndrome fibroblast cell lines. Hum. Genet. 105, 132 – 138.
155 VonKobbe,C.,May,A.,Grandori,C.,andBohr,V. A.(2004)
Werner syndrome cells escape hydrogen peroxide-induced
cell proliferation arrest. FASEB J. 18, 1970 – 1972.
156 Szekely, A. M., Bleichert, F., Numann, A., Van Komen, S.,
Manasanch, E., Ben Nasr, A., Canaan, A., and Weissman,
S. M. (2005) Werner protein protects nonproliferating cells
from oxidative DNA damage. Mol. Cell. Biol. 25, 10492 –
10506.
157 von Kobbe, C., Harrigan, J. A., May, A., Opresko, P. L.,
Dawut,L., Cheng, W. H., and Bohr, V. A. (2003) Centralrole
fortheWernersyndromeprotein/poly(ADP-ribose)polymer-
ase 1 complex in the poly(ADP-ribosyl)ation pathway after
DNA damage. Mol. Cell. Biol. 23, 8601 – 8613.
158 Blank, A., Bobola, M. S., Gold, B., Varadarajan, S., Kolstoe,
DD,Meade,E. H.,Rabinovitch,P. S.,Loeb,L. A.,andSilber,
J. R. (2004) The Werner syndrome protein confers resistance
to the DNA lesions N3-methyladenine and O6-methylgua-
nine:implicationsforWRNfunction.DNARepair(Amst.)3,
629 – 638.
159 Harrigan, J. A., Wilson, D. M., 3rd, Prasad, R., Opresko,
P. L.,Beck,G.,May,A.,Wilson,S. H.,andBohr,V. A.(2006)
TheWernersyndromeproteinoperatesinbaseexcisionrepair
and cooperates with DNA polymerase beta. Nucleic Acids
Res. 34, 745 – 754.
160 Harrigan, J. A., Opresko, P. L., von Kobbe, C., Kedar, P. S.,
Prasad, R., Wilson, S. H., and Bohr, V. A. (2003) The Werner
syndrome protein stimulates DNA polymerase beta strand
displacement synthesis via its helicase activity. J. Biol. Chem.
278, 22686 – 22695.
161 Ahn, B., Harrigan, J. A., Indig, F. E., Wilson, D. M., 3rd, and
Bohr, V. A. (2004) Regulation of WRN helicase activity in
humanbaseexcisionrepair.J.Biol.Chem.279,53465 – 53474.
162 Frosina, G., Fortini, P., Rossi, O., Carrozzino, F., Raspaglio,
G., Cox, L. S., Lane, D. P., Abbondandalo, A., and Dogliotti,
E. (1996) Two pathways for base excision repair in mamma-
lian cells. J. Biol. Chem. 271, 9573 – 9578.
163 Brosh, R. M., Jr., Orren, D. K., Nehlin, J. O., Ravn, P. H.,
Kenny,M. K.,Machwe,A.,andBohr,V. A.(1999)Functional
and physical interaction between WRN helicase and human
replication protein A. J. Biol. Chem. 274, 18341 – 18350.
164 Lebel, M., Lavoie, J., Gaudreault, I., Bronsard, M., and
Drouin, R. (2003) Genetic cooperation between the Werner
syndrome protein and poly(ADP-ribose) polymerase-1 in
preventing chromatid breaks, complex chromosomal rear-
rangements, and cancer in mice. Am. J. Pathol. 162, 1559 –
1569.
2638 L. S. Cox and R. G. A. Faragher Progeroid syndromes: biology and therapy165 von Kobbe, C., Harrigan, J. A., Schreiber, V., Stiegler, P.,
Piotrowski, J., Dawut, L., and Bohr, V. A. (2004) Poly(ADP-
ribose) polymerase 1 regulates both the exonuclease and
helicase activities of the Werner syndrome protein. Nucleic
Acids Res. 32, 4003 – 4014.
166 Gray, M. D., Wang, L., Youssoufian, H., Martin, G. M., and
Oshima, J. (1998) Werner helicase is localized to transcrip-
tionally active nucleoli of cycling cells. Exp. Cell Res. 242,
487 – 494.
167 Shiratori, M., Suzuki, T., Itoh, C., Goto, M., Furuichi,Y., and
Matsumoto, T. (2002) WRN helicase accelerates the tran-
scription of ribosomal RNA as a component of an RNA
polymerase I-associated complex. Oncogene 21, 2447 – 2454.
168 Balajee,A. S.,Machwe,A.,May,A.,Gray,M. D.,Oshima,J.,
Martin, G. M., Nehlin, J. O., Brosh, R., Orren, D. K., and
Bohr, V. A. (1999) The Werner syndrome protein is involved
inRNApolymeraseIItranscription.Mol.Biol.Cell10,2655 –
2668.
169 Turaga, R. V.N., Massip, L., Chavz, A., Johnson, F. B., and
Lebel,M. (in press) Werner syndromeproteinpreventsDNA
breaks upon chromatin structure alteration. Aging Cell.
170 Cogoni, C. and Macino, G. (1999) Posttranscriptional gene
silencing in Neurospora by a RecQ DNA helicase. Science
286, 2342 – 2344.
171 Ketting, R. F., Haverkamp, T. H., van Luenen, H. G., and
Plasterk, R. H. (1999) Mut-7 of C. elegans, required for
transposon silencing and RNA interference, is a homolog of
Werner syndrome helicase and RNaseD. Cell 99, 133 – 141.
172 Glazov,E.,Phillips,K.,Budziszewski,G. J.,Schob,H.,Meins,
F., Jr., and Levin, J. Z. (2003) A gene encoding an RNase D
exonuclease-like protein is required for post-transcriptional
silencing in Arabidopsis. Plant J. 35, 342 – 349.
173 Watt, P. M., Louis, E. J., Borts, R. H., and Hickson, I. D.
(1995) Sgs1: a eukaryotic homolog of E. coli RecQ that
interacts with topoisomerase II in vivo and is required for
faithful chromosome segregation. Cell 81, 253 – 260.
174 Win, T. Z., Mankouri, H. W., Hickson, I. D., and Wang, S. W.
(2005) A role for the fission yeast Rqh1 helicase in chromo-
some segregation. J. Cell Sci. 118, 5777 – 5784.
175 Uhlmann,F.andNasmyth,K.(1998)Cohesionbetweensister
chromatids must be established during DNA replication.
Curr. Biol. 8, 1095 – 1101.
176 Leng,M.,Chan,D. W.,Luo,H.,Zhu,C.,Qin,J.,andWang,Y.
(2006) MPS1-dependent mitotic BLM phosphorylation is
important for chromosome stability. Proc. Natl. Acad. Sci.
USA 103, 11485 – 11490.
177 Salk, D. (1982) Werner s syndrome: a review of recent
research with an analysis of connective tissue metabolism,
growth control of cultured cells, and chromosomal aberra-
tions. Hum. Genet. 62 1 – 15.
178 Faragher, R. G., Kill, I. R., Hunter, J. A., Pope, F. M.,
Tannock, C., and Shall, S. (1993) The gene responsible for
Werner syndrome may be a cell division ”counting” gene.
Proc. Natl. Acad. Sci. USA 90, 12030 – 12034.
179 Choi, D., Whittier, P. S., Oshima, J., and Funk, W. D. (2001)
Telomerase expression prevents replicative senescence but
does not fully reset mRNA expression patterns in Werner
syndrome cell strains. FASEB J. 15, 1014 – 1020.
180 Ouellette,M. M.,McDaniel,L. D.,Wright,W. E.,Shay,J. W.,
and Schultz, R. A. (2000) The establishment of telomerase-
immortalized cell lines representing human chromosome
instability syndromes. Hum. Mol. Genet. 9, 403 – 411.
181 James, S. E., Faragher, R. G., Burke, J. F., Shall, S., and
Mayne, L. V. (2000) Werner s syndrome T lymphocytes
display a normal in vitro life-span. Mech. Ageing Dev. 121,
139 – 149.
182 Fukuchi, K., Tanaka, K., Kumahara, Y., Marumo, K., Pride,
M. B., Martin, G. M., and Monnat, R. J., Jr. (1990) Increased
frequency of 6-thioguanine-resistant peripheral blood lym-
phocytesinWernersyndromepatients.Hum.Genet.84,249 –
252.
183 Johnson, F. B., Marciniak, R. A., McVey, M., Stewart, S. A.,
Hahn, W. C., and Guarente, L. (2001) The Saccharomyces
cerevisiae WRN homolog Sgs1p participates in telomere
maintenance in cells lacking telomerase. EMBO J. 20, 905 –
913.
184 Lebel, M. and Leder, P. (1998) A deletion within the murine
Werner syndrome helicase induces sensitivity to inhibitors of
topoisomerase and loss of cellular replicative capacity. Proc.
Natl. Acad. Sci. USA 95, 13097 – 13102.
185 Wang, L., Ogburn, C. E., Ware, C. B., Ladiges, W. C.,
Youssoufian, H., Martin, G. M., and Oshima, J. (2000)
Cellular Werner phenotypes in mice expressing a putative
dominant-negative human WRN gene. Genetics 154, 357 –
362.
186 Chang, S., Multani, A. S., Cabrera, N. G., Naylor, M. L.,
Laud, P., Lombard, D., Pathak, S., Guarente, L., and
DePinho, R. A. (2004) Essential role of limiting telomeres
in the pathogenesis of Werner syndrome. Nat. Genet. 36,
877 – 882.
187 Goto, M., Miller, R. W., Ishikawa, Y., and Sugano, H. (1996)
Excess of rare cancers in Werner syndrome (adult progeria)
Cancer Epidemiol. Biomarkers Prev. 5, 239 – 246.
188 Yokote, K., Hara, K., Mori, S., Kadowaki, T., Saito, Y., and
Goto, M. (2004) Dysadipocytokinemia in werner syndrome
and its recovery by treatment with pioglitazone. Diabetes
Care 27, 2562 – 2563.
189 Hashimoto, N., Hatanaka, S., Yokote, K., Kurosawa, H.,
Yoshida, T., Iwai, R., Takahashi, H., Yoshida, K., Horie, A.,
Sakurai, K., Yagui, K., Saito, Y., and Yoshida, S. (2007) A
patient with Werner syndrome and adiponectin gene muta-
tion. Diabetes Res. Clin. Pract. 75, 27 – 29.
190 Yokote, K., Honjo, S., Kobayashi, K., Fujimoto, M., Kawa-
mura, H., Mori, S., and Saito, Y. (2004) Metabolic improve-
mentandabdominalfatredistributioninWernersyndromeby
pioglitazone. J. Am. Geriatr. Soc. 52, 1582 – 1583.
191 Davis, T., Baird, D. M., Haughton, M. F., Jones, C. J., and
Kipling, D. (2005) Prevention of accelerated cell aging in
Werner syndrome using a p38 mitogen-activated protein
kinase inhibitor. J. Gerontol. A Biol. Sci. Med. Sci. 60, 1386 –
1393.
192 Hattori, S., Kasai, M., Namatame, T., Hattori, Y., and Kasai,
K. (2004) Pioglitazone treatment of insulin resistance in a
patient with Werner s syndrome. Diabetes Care 27, 3021 –
3022.
193 Fossel, M. B. (2004) Cells, Aging and Human Disease, p. 503.
Oxford University Press, Oxford.
194 DeSandre-Giovannoli,A.,Bernard,R.,Cau,P.,Navarro,C.,
Amiel,J.,Boccaccio, I., Lyonnet,S.,Stewart,C. L.,Munnich,
A.,LeMerrer,M.,andLevy,N.(2003)Lamin:atruncationin
Hutchinson-Gilford progeria. Science 300, 2055.
195 Eriksson, M., Brown, W. T., Gordon, L. B., Glynn, M. W.,
Singer, J., Scott, L., Erdos, M. R., Robbins, C. M., Moses,
T. Y., Berglund, P., Dutra, A., Pak, E., Durkin, S., Csoka,
A. B., Boehnke, M., Glover, T. W., and Collins, F. S. (2003)
Recurrent de novo point mutations in lamin A cause
Hutchinson-Gilford progeria syndrome. Nature 423, 293 –
298.
196 Broers, J. L., Machiels, B. M., Kuijpers, H. J., Smedts, F., van
den Kieboom, R., Raymond, Y., and Ramaekers, F. C. (1997)
A- and B-type lamins are differentially expressed in normal
human tissues. Histochem. Cell Biol. 107, 505 – 517.
197 Hutchison, C. J. and Worman, H. J. (2004) A-type lamins:
guardians of the soma? Nat. Cell Biol. 6, 1062 – 1067.
198 Hutchison, C. J., Bridger, J. M., Cox, L. S., and Kill, I. R.
(1994) Weaving a pattern from disparate threads: lamin
functioninnuclearassemblyandDNAreplication.J.CellSci.
107, 3259 – 3269.
199 Cox, L. S. and Hutchison, C. J. (1994) Nuclear Envelope
Assembly and Disassembly. In: Subcellular Biochemistry,
p. 263 – 325. Maddy, A. H. and Harris, J. A.  (Eds.). Plenum,
New York.
Cell.Mol.Life Sci. Vol.64, 2007 Review Article 2639200 Courvalin, J. C., Segil, N., Blobel, G., and Worman, H. J.
(1992) The lamin B receptor of the inner nuclear membrane
undergoes mitosis-specific phosphorylation and is a substrate
for p34cdc2-type protein kinase. J. Biol. Chem. 267, 19035 –
19038.
201 Heald, R. and McKeon, F. (1990) Mutations of phosphory-
lation sites in lamin A that prevent nuclear lamina disassem-
bly in mitosis. Cell 61, 579 – 589.
202 Goldman, R. D., Gruenbaum, Y., Moir, R. D., Shumaker,
D. K.,andSpann,T. P.(2002)Nuclearlamins:buildingblocks
of nuclear architecture. Genes Dev. 16, 533 – 547.
203 Goldman, R. D., Goldman, A. E., and Shumaker, D. K.
(2005) Nuclear lamins: building blocks of nuclear structure
and function. Novartis Found Symp 264, 3 – 16; discussion
16 – 21, 227 – 230.
204 Navarro, C. L., Cau, P., and Levy, N. (2006) Molecular bases
of progeroid syndromes. Hum. Mol. Genet. 15 (Suppl. 2),
R151 – 161.
205 D Apice,M. R.,Tenconi,R.,Mammi,I.,vandenEnde,J.,and
Novelli, G. (2004) Paternal origin of LMNA mutations in
Hutchinson-Gilford progeria. Clin. Genet. 65, 52 – 54.
206 De Sandre-Giovannoli, A. and Levy, N. (2006) Altered
splicing in prelamin A-associated premature aging pheno-
types. Prog. Mol. Subcell. Biol. 44, 199 – 232.
207 Broers, J. L., Hutchison, C. J., and Ramaekers, F. C. (2004)
Laminopathies. J. Pathol. 204, 478 – 488.
208 Broers, J. L., Ramaekers, F. C., Bonne, G., Yaou, R. B., and
Hutchison, C. J. (2006) Nuclear lamins: laminopathies and
their role in premature ageing. Physiol. Rev. 86, 967 – 1008.
209 Wuyts, W., Biervliet, M., Reyniers, E., D Apice, M. R.,
Novelli, G., and Storm, K. (2005) Somatic and gonadal
mosaicism in Hutchinson-Gilford progeria. Am. J. Med.
Genet. A 135, 66 – 68.
210 Fong, L. G., Ng, J. K., Meta, M., Cote, N., Yang, S. H.,
Stewart, C. L., Sullivan, T., Burghardt, A., Majumdar, S.,
Reue, K., Bergo, M. O., and Young, S. G. (2004) Hetero-
zygosity for Lmna deficiency eliminates the progeria-like
phenotypesinZmpste24-deficientmice.Proc.Natl.Acad.Sci.
USA 101, 18111 – 18116.
211 Goldman, R. D., Shumaker, D. K., Erdos, M. R., Eriksson,
M., Goldman, A. E., Gordon, L. B., Gruenbaum, Y., Khuon,
S., Mendez, M., Varga, R., and Collins, F. S. (2004) Accumu-
lation of mutant lamin A causes progressive changes in
nuclear architecture in Hutchinson-Gilford progeria syn-
drome. Proc. Natl. Acad. Sci. USA 101, 8963 – 8968.
212 Yang, S. H., Bergo, M. O., Toth, J. I., Qiao, X., Hu, Y.,
Sandoval, S., Meta, M., Bendale, P., Gelb, M. H., Young,
S. G., and Fong, L. G. (2005) Blocking protein farnesyltrans-
ferase improves nuclear blebbing in mouse fibroblasts with a
targeted Hutchinson-Gilford progeria syndrome mutation.
Proc. Natl. Acad. Sci. USA 102, 10291 – 10296.
213 Verstraeten, V. L., Broers, J. L., van Steensel, M. A., Zinn-
Justin, S., Ramaekers, F. C., Steijlen, P. M., Kamps, M.,
Kuijpers, H. J., Merckx, D., Smeets, H. J., Hennekam, R. C.,
Marcelis, C. L.,andvandenWijngaard,A. (2006)Compound
heterozygosity for mutations in LMNA causes a progeria
syndrome without prelamin A accumulation. Hum. Mol.
Genet. 15, 2509 – 2522.
214 Plasilova, M., Chattopadhyay, C., Pal, P., Schaub, N. A.,
Buechner, S. A., Mueller, H., Miny, P., Ghosh, A., and
Heinimann, K. (2004) Homozygous missense mutation in the
lamin A/C gene causes autosomal recessive Hutchinson-
Gilford progeria syndrome. J. Med. Genet. 41, 609 – 614.
215 Navarro, C. L., De Sandre-Giovannoli, A., Bernard, R.,
Boccaccio, I., Boyer, A., Genevieve, D., Hadj-Rabia, S.,
Gaudy-Marqueste, C., Smitt, H. S., Vabres, P., Faivre, L.,
Verloes,A.,VanEssenetal.(2004)LaminAandZMPSTE24
(FACE-1) defects cause nuclear disorganization and identify
restrictive dermopathy as a lethal neonatal laminopathy.
Hum. Mol. Genet. 13, 2493 – 2503.
216 Navarro, C. L., Cadinanos, J., De Sandre-Giovannoli, A.,
Bernard, R., Courrier, S., Boccaccio, I., Boyer, A., Kleijer,
W. J., Wagner, A., Giuliano, F., Beemer, F. A., Freije, J. M. et
al. (2005) Loss of ZMPSTE24 (FACE-1) causes autosomal
recessive restrictive dermopathy and accumulation of Lamin
A precursors. Hum. Mol. Genet. 14, 1503 – 1513.
217 Moulson, C. L., Go, G., Gardner, J. M., van der Wal, A. C.,
Smitt, J. H., van Hagen, J. M., and Miner, J. H. (2005)
Homozygous and compound heterozygous mutations in
ZMPSTE24 cause the laminopathy restrictive dermopathy.
J. Invest. Dermatol. 125, 913 – 919.
218 Agarwal, A. K., Fryns, J. P., Auchus, R. J., and Garg, A.
(2003) Zinc metalloproteinase, ZMPSTE24, is mutated in
mandibuloacral dysplasia. Hum. Mol. Genet. 12, 1995 – 2001.
219 Bridger, J. M. and Kill, I. R. (2004) Aging of Hutchinson-
Gilford progeria syndrome fibroblasts is characterised by
hyperproliferation and increased apoptosis. Exp. Gerontol.
39, 717 – 724.
220 Scaffidi, P. and Misteli, T. (2005) Reversal of the cellular
phenotype in the premature aging disease Hutchinson-
Gilford progeria syndrome. Nat. Med. 11, 440 – 445.
221 Columbaro, M., Capanni, C., Mattioli, E., Novelli, G.,
Parnaik, V. K., Squarzoni, S., Maraldi, N. M., and Lattanzi,
G. (2005) Rescue of heterochromatin organization in Hutch-
inson-Gilford progeria by drug treatment. Cell. Mol. Life Sci.
62, 2669 – 2678.
222 Meier, J., Campbell, K. H., Ford, C. C., Stick, R., and
Hutchison, C. J. (1991) The role of lamin LIII in nuclear
assembly and DNA replication, in cell-free extracts of
Xenopus eggs. J. Cell Sci. 98, 271 – 279.
223 Moir, R. D., Spann, T. P., Herrmann, H., and Goldman, R. D.
(2000) Disruption of nuclear lamin organization blocks the
elongation phase of DNA replication. J. Cell Biol. 149, 1179–
1192.
224 Spann, T. P., Moir, R. D., Goldman, A. E., Stick, R., and
Goldman, R. D. (1997) Disruption of nuclear lamin organ-
ization alters the distribution of replication factors and
inhibits DNA synthesis. J. Cell Biol. 136, 1201 – 1212.
225 Goldberg, M., Jenkins, H., Allen, T., Whitfield, W. G., and
Hutchison, C. J. (1995) Xenopus lamin B3 has a direct role in
the assembly of a replication competent nucleus: evidence
from cell-free egg extracts. J Cell Sci 108, 3451 – 3461.
226 Spann, T. P., Goldman, A. E., Wang, C., Huang, S., and
Goldman, R. D. (2002) Alteration of nuclear lamin organ-
ization inhibits RNA polymerase II-dependent transcription.
J. Cell Biol. 156, 603 – 608.
227 Van Berlo, J. H., Voncken, J. W., Kubben, N., Broers, J. L.,
Duisters, R., van Leeuwen, R. E., Crijns, H. J., Ramaekers,
F. C., Hutchison, C. J., and Pinto, Y. M. (2005) A-type lamins
are essential for TGF-beta1 induced PP2A to dephosphor-
ylate transcriptionfactors. Hum. Mol. Genet. 14, 2839 – 2849.
228 Liu, B., Wang, J., Chan, K. M., Tjia, W. M., Deng, W., Guan,
X., Huang, J. D., Li, K. M., Chau, P. Y., Chen, D. J., Pei, D.,
Pendas, A. M. et al. (2005) Genomic instability in laminop-
athy-based premature aging. Nat. Med. 11, 780 – 785.
229 Pendas, A. M., Zhou, Z., Cadinanos, J., Freije, J. M., Wang, J.,
Hultenby, K., Astudillo, A., Wernerson, A., Rodriguez, F.,
Tryggvason,K.,andLopez-Otin,C.(2002)DefectiveprelaminA
processing and muscular and adipocyte alterations in Zmpste24
metalloproteinase-deficient mice. Nat. Genet. 31, 94–99.
230 Mounkes, L. C., Kozlov, S., Hernandez, L., Sullivan, T., and
Stewart, C. L. (2003) A progeroid syndromein mice is caused
by defects in A-type lamins. Nature 423, 298 – 301.
231 Varela, I., Cadinanos, J., Pendas, A. M., Gutierrez-Fernan-
dez, A., Folgueras, A. R., Sanchez, L. M., Zhou, Z., Rodri-
guez, F. J., Stewart, C. L., Vega, J. A., Tryggvason, K., Freije,
J. M., and Lopez-Otin, C. (2005) Accelerated ageing in mice
deficient in Zmpste24 protease is linked to p53 signalling
activation. Nature 437, 564 – 568.
232 Capanni, C., Mattioli, E., Columbaro, M., Lucarelli, E.,
Parnaik, V. K., Novelli, G., Wehnert, M., Cenni, V., Maraldi,
N. M., Squarzoni, S., and Lattanzi, G. (2005) Altered pre-
lamin A processing is a common mechanism leading to
lipodystrophy. Hum. Mol. Genet. 14, 1489 – 1502.
2640 L. S. Cox and R. G. A. Faragher Progeroid syndromes: biology and therapy233 Kim, J. B., Wright, H. M., Wright, M., and Spiegelman,B. M.
(1998) ADD1/SREBP1 activates PPARgamma through the
production of endogenous ligand. Proc. Natl. Acad. Sci. USA
95, 4333 – 4337.
234 Krimm, I., Ostlund, C., Gilquin, B., Couprie, J., Hossenlopp,
P., Mornon, J. P., Bonne, G., Courvalin, J. C., Worman, H. J.,
and Zinn-Justin, S. (2002) The Ig-like structure of the C-
terminal domain of lamin A/C, mutated in muscular dystro-
phies, cardiomyopathy, and partial lipodystrophy. Structure
10, 811 – 823.
235 Huang, S., Chen, L., Libina, N., Janes, J., Martin, G. M.,
Campisi, J., and Oshima, J. (2005) Correction of cellular
phenotypes of Hutchinson-Gilford Progeria cells by RNA
interference. Hum. Genet. 118, 444 – 450.
236 Mallampalli, M. P., Huyer, G., Bendale, P., Gelb, M. H., and
Michaelis, S. (2005) Inhibiting farnesylation reverses the
nuclear morphology defect in a HeLa cell model for
Hutchinson-Gilford progeria syndrome. Proc. Natl. Acad.
Sci. USA 102, 14416 – 14421.
237 Yang, S. H., Meta, M., Qiao, X., Frost, D., Bauch, J.,
Coffinier, C., Majumdar, S., Bergo, M. O., Young, S. G., and
Fong, L. G. (2006) A farnesyltransferase inhibitor improves
disease phenotypes in mice with a Hutchinson-Gilford
progeria syndrome mutation. J. Clin. Invest. 116, 2115 – 2121.
To access this journal online:
http://www.birkhauser.ch/CMLS
Cell.Mol.Life Sci. Vol.64, 2007 Review Article 2641